<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71966</article-id><article-id pub-id-type="doi">10.7554/eLife.71966</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>IRAK1-dependent Regnase-1-14-3-3 complex formation controls Regnase-1-mediated mRNA decay</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-245978"><name><surname>Akaki</surname><given-names>Kotaro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0059-3291</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-245979"><name><surname>Ogata</surname><given-names>Kosuke</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0634-3990</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-245980"><name><surname>Yamauchi</surname><given-names>Yuhei</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-245981"><name><surname>Iwai</surname><given-names>Noriki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-245982"><name><surname>Tse</surname><given-names>Ka Man</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-245983"><name><surname>Hia</surname><given-names>Fabian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7209-4312</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174231"><name><surname>Mochizuki</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-140260"><name><surname>Ishihama</surname><given-names>Yasushi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7714-203X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-245984"><name><surname>Mino</surname><given-names>Takashi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9562-008X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-217664"><name><surname>Takeuchi</surname><given-names>Osamu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1260-6232</contrib-id><email>otake@mfour.med.kyoto-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Medical Chemistry, Graduate School of Medicine, Kyoto University</institution><addr-line><named-content content-type="city">Kyoto</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution>Graduate School of Biostudies, Kyoto University</institution><addr-line><named-content content-type="city">Kyoto</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution>Department of Molecular and Cellular BioAnalysis, Graduate School of Pharmaceutical Sciences, Kyoto University</institution><addr-line><named-content content-type="city">Kyoto</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution>Laboratory of Mathematical Biology, Institute for Frontier Life and Medical Sciences, Kyoto University</institution><addr-line><named-content content-type="city">Kyoto</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Senior Editor</role><aff><institution>Yale School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><role>Reviewing Editor</role><aff><institution>McGill University</institution><country>Canada</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>12</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e71966</elocation-id><history><date date-type="received" iso-8601-date="2021-07-06"><day>06</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-08"><day>08</day><month>10</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-07-15"><day>15</day><month>07</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.07.15.452458"/></event></pub-history><permissions><copyright-statement>© 2021, Akaki et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Akaki et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71966-v3.pdf"/><abstract><p>Regnase-1 is an endoribonuclease crucial for controlling inflammation by degrading mRNAs encoding cytokines and inflammatory mediators in mammals. However, it is unclear how Regnase-1-mediated mRNA decay is controlled in interleukin (IL)-1β- or Toll-like receptor (TLR) ligand-stimulated cells. Here, by analyzing the Regnase-1 interactome, we found that IL-1β or TLR stimulus dynamically induced the formation of Regnase-1-β-transducin repeat-containing protein (βTRCP) complex. Importantly, we also uncovered a novel interaction between Regnase-1 and 14-3-3 in both mouse and human cells. In IL-1R/TLR-stimulated cells, the Regnase-1-14-3-3 interaction is mediated by IRAK1 through a previously uncharacterized C-terminal structural domain. Phosphorylation of Regnase-1 at S494 and S513 is critical for Regnase-1-14-3-3 interaction, while a different set of phosphorylation sites of Regnase-1 is known to be required for the recognition by βTRCP and proteasome-mediated degradation. We found that Regnase-1-14-3-3 and Regnase-1-βTRCP interactions are not sequential events. Rather, 14-3-3 protects Regnase-1 from βTRCP-mediated degradation. On the other hand, 14-3-3 abolishes Regnase-1-mediated mRNA decay by inhibiting Regnase-1-mRNA association. In addition, nuclear-cytoplasmic shuttling of Regnase-1 is abrogated by 14-3-3 interaction. Taken together, the results suggest that a novel inflammation-induced interaction of 14-3-3 with Regnase-1 stabilizes inflammatory mRNAs by sequestering Regnase-1 in the cytoplasm to prevent mRNA recognition.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>post-transcriptional regulation</kwd><kwd>inflammation</kwd><kwd>14-3-3</kwd><kwd>phosphorylation</kwd><kwd>RNase</kwd><kwd>interactome</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP20gm4010002</award-id><principal-award-recipient><name><surname>Takeuchi</surname><given-names>Osamu</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>Core-to-Core Program</award-id><principal-award-recipient><name><surname>Takeuchi</surname><given-names>Osamu</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>221S0002</award-id><principal-award-recipient><name><surname>Mino</surname><given-names>Takashi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>16H06279</award-id><principal-award-recipient><name><surname>Mino</surname><given-names>Takashi</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>18H05278</award-id><principal-award-recipient><name><surname>Takeuchi</surname><given-names>Osamu</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>19H03488</award-id><principal-award-recipient><name><surname>Mino</surname><given-names>Takashi</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>21ae0121030</award-id><principal-award-recipient><name><surname>Takeuchi</surname><given-names>Osamu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Regnase-1, an RNase suppressing proinflammatory mRNAs, interacts with 14-3-3, which diminishes cytokine mRNA recognition and the nuclear-cytoplasmic shuttling of Regnase-1 under inflammatory conditions.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The expression of proinflammatory cytokines is the hallmark of innate immune responses against microbial infection. Whereas inflammatory responses are critical for the elimination of invading pathogens, excess and chronic inflammation can culminate in tissue destruction and autoimmune diseases. When innate immune cells encounter pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), they are sensed by pattern-recognition receptors such as Toll-like receptors (TLRs), triggering the transcription of inflammatory genes (<xref ref-type="bibr" rid="bib10">Fitzgerald and Kagan, 2020</xref>; <xref ref-type="bibr" rid="bib46">Takeuchi and Akira, 2010</xref>).</p><p>The expression of inflammatory genes is also controlled by post-transcriptional mechanisms to facilitate or limit inflammatory responses (<xref ref-type="bibr" rid="bib4">Anderson, 2010</xref>; <xref ref-type="bibr" rid="bib6">Carpenter et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Turner and Díaz-Muñoz, 2018</xref>). Regnase-1 (also referred to as Mcpip1, Gene name: <italic>Zc3h12a</italic>), an RNase, is a critical regulator of inflammation. Regnase-1 binds to and degrades inflammatory mRNAs such as <italic>Il6</italic> or <italic>Il12b</italic> by recognizing stem-loop structures present in the 3’ untranslated regions (<xref ref-type="bibr" rid="bib28">Matsushita et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Mino et al., 2015</xref>). <italic>Zc3h12a</italic>-deficient mice exhibit an autoimmune phenotype, indicating its importance as a negative regulator of inflammation (<xref ref-type="bibr" rid="bib28">Matsushita et al., 2009</xref>; <xref ref-type="bibr" rid="bib49">Uehata et al., 2013</xref>). Regnase-1 efficiently suppresses the expression of its target genes by degrading CBP80-bound mRNAs during the pioneer-round of translation by associating with ribosome and a helicase protein, UPF1 (<xref ref-type="bibr" rid="bib30">Mino et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Mino et al., 2019</xref>). CBP80 binds to newly synthesized mRNAs in the nucleus and is replaced by eIF4E after the pioneer round of translation following mRNA export from the nucleus (<xref ref-type="bibr" rid="bib26">Maquat et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Müller-McNicoll and Neugebauer, 2013</xref>). Thus, it is possible that Regnase-1 recognizes target mRNAs in the steps leading to the pioneer round of translation.</p><p>The stability of cytokine mRNAs is dynamically regulated in innate immune cells under inflammatory conditions (<xref ref-type="bibr" rid="bib6">Carpenter et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Hao and Baltimore, 2009</xref>; <xref ref-type="bibr" rid="bib48">Turner and Díaz-Muñoz, 2018</xref>). Post-translational control of Regnase-1 in response to inflammatory stimuli contributes to extending half-lives of inflammatory mRNAs. Stimulation of cells with TLR-ligands, IL-1β, or IL-17 results in the activation of IκB kinases (IKKs), which phosphorylate Regnase-1 at S435 and S439, in addition to IκBα (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Kakiuchi et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Nanki et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Tanaka et al., 2019</xref>). Regnase-1, phosphorylated at S435 and S439 is subsequently recognized by βTRCP, one of the components of the SKP1-CUL1-F-box (SCF) complex, which induces K48-linked polyubiquitination of Regnase-1, followed by proteasome-mediated degradation (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>). On the other hand, these stimuli also induce transcription of <italic>Zc3h12a</italic> (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>). Consequently, the protein level of Regnase-1 drastically changes during these stimulations; Regnase-1 levels decrease immediately after the stimulation and then increase to levels higher than its pre-stimulation. However, the post-translational regulatory mechanism of Regnase-1 following inflammatory stimuli is still not fully elucidated.</p><p>14-3-3 family proteins are conserved among species and are known to form hetero- or homodimer (<xref ref-type="bibr" rid="bib2">Aitken, 2006</xref>; <xref ref-type="bibr" rid="bib40">Pennington et al., 2018</xref>). The 14-3-3 dimer binds to various phosphorylated proteins using its two phosphor-S/T binding pockets which recognize unique phospho-peptides (<xref ref-type="bibr" rid="bib33">Muslin et al., 1996</xref>; <xref ref-type="bibr" rid="bib57">Yaffe et al., 1997</xref>). Although 14-3-3 itself has no enzymatic activity, 14-3-3 is known to modulate the properties of target proteins, such as protein stability or localization (<xref ref-type="bibr" rid="bib2">Aitken, 2006</xref>; <xref ref-type="bibr" rid="bib40">Pennington et al., 2018</xref>).</p><p>In this study, we utilized an interactome-based approach to isolate Regnase-1 protein complexes and found that TLR-ligand, IL-1β, or IL-17 stimulation induces the formation of the Regnase-1-14-3-3 complex. The phosphorylation of Regnase-1 at S494 and S513 is responsible for binding with 14-3-3, which in turn stabilizes Regnase-1 protein by excluding βTRCP. However, 14-3-3-bound Regnase-1 is not functional because 14-3-3 prevents Regnase-1 from recognizing target mRNAs. In addition, we found that nuclear-cytoplasmic shuttling of Regnase-1 is inhibited by 14-3-3’s association with Regnase-1. Collectively, we identified a novel 14-3-3-mediated molecular mechanism which controls Regnase-1; a distinctly independent mechanism from βTRCP-mediated protein degradation of Regnase-1.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Regnase-1 interactome analysis revealed dynamic recruitment of 14-3-3 upon stimulation</title><p>To comprehensively uncover Regnase-1-associating proteins in steady state and under inflammatory conditions, we stimulated HeLa cells expressing FLAG-HA-tagged Regnase-1 with or without IL-1β and immunoprecipitated Regnase-1 immediately after the treatment with a crosslinking reagent, Dithiobis(succinimidyl propionate) (DSP) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Consistent with the previous reports, mass spectrometry analysis revealed that Regnase-1 interacted with translation-related proteins such as ribosomal proteins in unstimulated cells (<xref ref-type="bibr" rid="bib30">Mino et al., 2015</xref>). Whereas IL-1β stimulation reduced the association between Regnase-1 and translation-related proteins, the stimulation strongly induced the association between Regnase-1 and SCF complex proteins such as βTRCP1/2, CUL1, and SKP1 (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>). In addition to these proteins, we identified 14-3-3 family proteins as novel Regnase-1-associating proteins under IL-1β-stimulated conditions (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Consistently, immunoprecipitation analysis revealed that endogenous Regnase-1 was co-precipitated with Myc-tagged 14-3-3ε as well as with HA-tagged βTRCP in HeLa cells in response to IL-1β stimulation (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>IL-1β or TLR1/2/4/7/8/9-ligand stimulation induces Regnase-1-14-3-3 interaction.</title><p>(<bold>A</bold>) Schematic illustration of the DSP-crosslinking workflow. (<bold>B</bold>) Protein-protein interaction of the Regnase-1 (Reg1)-associating proteins. Each node represents Regnase-1 associating protein. The proteins whose association with Regnase-1 is weakened or enhanced in IL-1β-stimulated cells are colored in blue or red, respectively. (<bold>C</bold>) Immunoblot analysis of immunoprecipitates (IP: Myc or IP: HA) and WCL (whole cell lysates) from HeLa cells transiently expressing Myc-14-3-3ε and HA-βTRCP1 stimulated with IL-1β (10 ng/ml) for indicated time. (<bold>D</bold>) Immunoblot analysis of immunoprecipitates (IP: Myc) and WCL from RAW264.7 or RAW264.7 stably expressing Myc-14-3-3ε stimulated with Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml), poly I:C (100 μg/ml), LPS (100 ng/ml), R848 (100 nM), or CpG DNA (1 μM) for 4 hr.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Regnase-1 binds to 14-3-3 and βTRCP in response to IL-1β stimulation.</title><p>Immunoblot analysis of immunoprecipitates (IP: Myc or IP: HA) and WCL from HeLa cells transiently expressing Myc-14-3-3ε and HA-βTRCP1 stimulated with IL-1β (10 ng/ml) for indicated time. The immunoprecipitates and corresponding WCL samples, both of which were used in <xref ref-type="fig" rid="fig1">Figure 1C</xref>, were applied to the same gel and the membranes were blotted with anti Regnase-1 antibody as well as anti-Actin antibody.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Regnase-1 binds to 14-3-3β/γ/ε/ζ/η/θ but not 14-3-3σ.</title><p>Immunoblot analysis of immunoprecipitates (IP: HA) and WCL from HeLa cells transiently expressing HA-14-3-3β, γ, ε, ζ, η, θ, or σ stimulated with IL-1β (10 ng/ml) for 4 hr.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig1-figsupp2-v3.tif"/></fig></fig-group><p>As the 14-3-3 family consists of seven paralogs in human and mouse (<xref ref-type="bibr" rid="bib2">Aitken, 2006</xref>), we investigated the binding of these members to Regnase-1 via immunoprecipitation (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Among seven of the 14-3-3 proteins, 14-3-3-β, γ, and ε strongly interacted with Regnase-1, while 14-3-3-ζ, η, and θ showed weak interaction. Interestingly, Regnase-1 failed to associate with 14-3-3-σ, the latter of which was reported to exclusively form a homodimer but not a heterodimer with other 14-3-3 isoforms (<xref ref-type="bibr" rid="bib51">Verdoodt et al., 2006</xref>).</p><p>To investigate if stimulation with TLR ligands also induces Regnase-1-14-3-3 binding, we stimulated RAW267.4 macrophages stably expressing Myc-14-3-3ε with Pam<sub>3</sub>CSK<sub>4</sub> (a ligand for TLR1/2), poly I:C (a ligand for TLR3), LPS (a ligand for TLR4), R848 (a ligand for TLR7/8), or CpG DNA (a ligand for TLR9), and immunoprecipitated 14-3-3ε with an anti-Myc antibody. The Regnase-1-14-3-3 interaction was induced by all TLR ligands tested except for poly I:C (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). All TLRs other than TLR3 signal through MyD88, while TLR3 utilizes TRIF as an adaptor to trigger intracellular signaling (<xref ref-type="bibr" rid="bib10">Fitzgerald and Kagan, 2020</xref>; <xref ref-type="bibr" rid="bib38">O'Neill et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Takeuchi and Akira, 2010</xref>). Considering that IL-1β signal is also dependent on MyD88 (<xref ref-type="bibr" rid="bib3">Akira et al., 2006</xref>), MyD88-dependent, but not TRIF-dependent, signaling pathways trigger the Regnase-1-14-3-3 binding.</p><p>Collectively, these results demonstrate that IL-1R/TLR stimulation induces dynamic remodeling of the Regnase-1-associating protein complex from translation machineries to SCF complexes and/or 14-3-3 proteins.</p></sec><sec id="s2-2"><title>Phosphorylation of Regnase-1 at S494 and S513 is necessary for Regnase-1-14-3-3 binding</title><p>Since 14-3-3 proteins are known to recognize phosphorylated proteins (<xref ref-type="bibr" rid="bib33">Muslin et al., 1996</xref>), we investigated if 14-3-3-bound Regnase-1 is phosphorylated by inflammatory stimuli. SDS-PAGE analysis revealed that Regnase-1 band migration was slower in samples stimulated with IL-1β or TLR ligands (except for a TLR3 ligand, poly I:C) - a hallmark of Regnase-1 phosphorylation (<xref ref-type="fig" rid="fig1">Figures 1C–D</xref> and <xref ref-type="fig" rid="fig2">2A</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Tanaka et al., 2019</xref>). Indeed, the mobility change of Regnase-1 was abolished when the cell lysates were treated with λ-protein phosphatase (λPP) (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). Furthermore, the Regnase-1 band in the 14-3-3-precipitate migrated slower; λPP treatment of the 14-3-3-precipitate abolished this phenomenon (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). Thus, 14-3-3 specifically binds to phosphorylated Regnase-1.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>IL-1β-induced phosphorylation of Regnase-1 at S494 and S513 is necessary for Regnase-1-14-3-3 binding.</title><p>(<bold>A</bold>) Immunoblot analysis of λPP-treated immunoprecipitates (IP: HA) and WCL from HeLa cells transiently expressing HA-14-3-3ε stimulated with IL-1β (10 ng/ml) for 4 hr. S.E.: short exposure, L.E.: long exposure. (<bold>B</bold>) The intensity of Regnase-1-bands in (<bold>A</bold>). (<bold>C</bold>) Quantitation of phosphosites on Regnase-1 in HeLa cells stimulated with or without IL-1β (10 ng/ml) for 4 hr. Each dot shows phosphosite quantitative ratio between IL-1β + and IL-1β -. Phosphosites with log<sub>2</sub> ratio &gt; one were colored with red. Black horizontal line shows Regnase-1 protein quantitative ratio derived from the average of non-phosphopeptide quantitative ratios, and its error bars show the standard deviation. (<bold>D</bold>) Immunoblot analysis of immunoprecipitates (IP: HA) and WCL from HeLa cells transiently expressing HA-14-3-3ε and FLAG-Regnase-1-WT or indicated mutants stimulated with IL-1β (10 ng/ml) for 4 hr. (<bold>E</bold>) Schematic illustration of Regnase-1 protein. The amino acid sequence including S494 and S513 shown in (<bold>F</bold>) is highlighted in green. NTD: N-terminal domain, ZF: Zinc finger domain, CTD: C-terminal domain. (<bold>F</bold>) The amino acid sequences including S494 and S513 of Regnase-1 from mouse and other indicated vertebrates. (<bold>G</bold>) Immunoblot analysis of immunoprecipitates (IP: Myc) and WCL from HeLa cells transiently expressing Myc-14-3-3ε, HA-IRAK1/2, and FLAG-Regnase-1-WT or indicated mutants. (<bold>H</bold>) Schematic illustration of IRAK1 protein. The amino acid sequence in CSD of IRAK1 and IRAK2 from mouse and other indicated vertebrates are also shown. DD: Death domain, CSD: C-terminal structural domain. (<bold>I</bold>) Immunoblot analysis of immunoprecipitates (IP: HA) and WCL from HeLa cells transiently expressing FLAG-Regnase-1-WT, HA-14-3-3ε, and Myc-IRAK1-WT or indicated mutants.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Regnase-1 bands migrate slower in LPS-stimulated samples.</title><p>Immunoblot analysis of <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>–/–</sup> thioglycollate-elicited PECs stimulated with LPS (100 ng/ml) for indicated time.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Candidate spectra of Regnase-1 phosphopeptides with confident site localization.</title><p>Only quantitatively altered phosphopeptides are shown. Fragment ions containing the N-(b-type ions) or C-(y-type ions) terminus are labeled with red (without neutral loss) or orange (with neutral-loss).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp2-v3.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Regnase-1-14-3-3 interaction is impaired in IRAK1/2-depleted cells.</title><p>HeLa cells were transfected with pX459 to knockout <italic>IRAK1</italic> and <italic>IRAK2</italic>. After the selection with puromycin, the cells were transfected with 14-3-3ε and stimulated with IL-1β (10 ng/ml) for 4 hr. Immunoblot analysis of immunoprecipitates (IP: HA) and WCL is shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp3-v3.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Schematic illustration of IRAK1.</title><p>The result of secondary structure prediction is shown below. DD: Death domain, CSD: C-terminal structural domain.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp4-v3.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>R663/K665A mutation does not abrogate IRAK1-mediated NF-κB activation.</title><p>Luciferase activity of HeLa cells transiently transfected with NF-κB luciferase reporter plasmid together with expression plasmids of IRAK1-WT or indicated mutants.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp5-v3.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title>IL-17A stimulation induces phosphorylation at S494 and S513 of Regnase-1.</title><p>Quantitation of phosphosites on Regnase-1 in HeLa cells stimulated with or without IL-17A (50 ng/ml) for 4 hr. Each dot shows phosphosite quantitative ratio between IL-17A+ and IL-17A-. Phosphosites with log<sub>2</sub> ratio &gt; 1 were colored with red. Black horizontal line shows Regnase-1 protein quantitative ratio derived from the average of non-phosphopeptide quantitative ratios, and its error bars show the standard deviation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp6-v3.tif"/></fig><fig id="fig2s7" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 7.</label><caption><title>Candidate spectra of Regnase-1 phosphopeptides with confident site localization.</title><p>Only quantitatively altered phosphopeptides are shown. Fragment ions containing the N-(b-type ions) or C-(y-type ions) terminus are labeled with red (without neutral loss) or orange (with neutral-loss).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp7-v3.tif"/></fig><fig id="fig2s8" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 8.</label><caption><title>IL-17A stimulation induces Regnase-1-14-3-3 association.</title><p>Immunoblot analysis of immunoprecipitates (IP: HA) and WCL from HeLa cells transiently expressing HA-14-3-3γ and FLAG-Regnase-1-WT or indicated mutants stimulated with IL-17A (50 ng/ml) for 4 hr.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig2-figsupp8-v3.tif"/></fig></fig-group><p>We next scrutinized Regnase-1 phosphorylation sites induced by IL-1β stimulation to identify phosphorylation sites critical for the Regnase-1-14-3-3 interaction. We purified FLAG-HA-Regnase-1 from HeLa cells stimulated with or without IL-1β and identified IL-1β-inducible phosphorylation sites by LC-MS/MS (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). We found that the phosphorylation at S21, S61, S62, S362, S439, S470, S494, and S513 of Regnase-1 was increased in response to IL-1β stimulation. To identify Regnase-1 phosphorylation sites responsible for binding with 14-3-3, we mutated serine residues on Regnase-1 phosphorylation sites into alanine and probed its association with 14-3-3. Among the Regnase-1-SA mutants, S494A and S513A mutants failed to be co-precipitated with 14-3-3 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), indicating that phosphorylation at both of S494 and S513 is necessary for the Regnase-1-14-3-3 interaction. Both phosphorylation sites harbor a pSxP sequence, which shows similarity with a known 14-3-3-binding motif, RxxpSxP, mode 1 (<xref ref-type="bibr" rid="bib57">Yaffe et al., 1997</xref>). Noteworthy, amino acid sequences surrounding S494 and S513 are highly conserved among many species (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>).</p><p>We next investigated the mechanism of how Regnase-1 phosphorylation is regulated by inflammatory stimuli. In response to IL-1β or TLR ligands stimulation, MyD88 associates with IRAK kinases, IRAK1 and IRAK2, via the death domain (<xref ref-type="bibr" rid="bib14">Gottipati et al., 2008</xref>; <xref ref-type="bibr" rid="bib55">Wesche et al., 1997</xref>). A part of C-terminal region of IRAKs in turn interacts with TRAF6 to activate NF-κB (<xref ref-type="bibr" rid="bib61">Ye et al., 2002</xref>). It was shown that <italic>Irak1</italic> and <italic>Irak2</italic> double deficiency abolished the phosphorylation of Regnase-1 after LPS stimulation (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>). We found that gene depletion of <italic>IRAK1/2</italic> using the CRISPR-Cas9 system in HeLa cells severely impaired the association between Regnase-1 and 14-3-3 as well as the phosphorylation of Regnase-1 in response to IL-1β stimulation (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Reciprocally, overexpression of IRAK1 and IRAK2-induced Regnase-1-14-3-3 binding (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). In contrast, the interaction between Regnase-1 and 14-3-3 was not induced by the expression of a kinase-inactive mutant (T209A) IRAK1 (<xref ref-type="bibr" rid="bib23">Kollewe et al., 2004</xref>) or a deletion mutant lacking death domain (Δ1–103) of IRAK1, indicating that the Regnase-1-14-3-3 binding requires the IRAK1 kinase activity as well as recruitment to MyD88 (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>). Although the C-terminal 619–710 portion of IRAK1 was also required for Regnase-1-14-3-3 binding, point mutations in TRAF6 binding sites (E541/E584/E704A) (<xref ref-type="bibr" rid="bib61">Ye et al., 2002</xref>) did not abolish the Regnase-1-14-3-3 binding (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>). In silico prediction suggested the presence of a C-terminal structural domain (CSD) in the 619–710 of IRAK1 (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). In the CSD of IRAK1, highly conserved amino acids, R663 and K665, are critical for the Regnase-1-14-3-3 binding (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>), suggesting that the CSD of IRAK1 controls Regnase-1-14-3-3 interaction irrespective of the recruitment of TRAF6. Of note, the R663/K665A mutant IRAK1 was capable of activating NF-κB (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>), indicating that the IRAK1 C-terminal region has two distinct functions: NF-κB activation through TRAF6-binding sites and the induction of Regnase-1-14-3-3 interaction through the CSD.</p><p>S494 and S513 of Regnase-1 are also reported to be phosphorylated by overexpression of Act1 together with TANK-binding kinase 1 (TBK1) or IKK-i/ε, which mimics IL-17 signaling (<xref ref-type="bibr" rid="bib47">Tanaka et al., 2019</xref>). We detected phosphorylation at S494 and S513 of Regnase-1 in IL-17A-stimulated cells as well as IL-1β-stimulated cells by LC-MS/MS (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplements 6</xref> and <xref ref-type="fig" rid="fig2s7">7</xref>). Furthermore, we found that IL-17A stimulation also induced Regnase-1-14-3-3 binding (<xref ref-type="fig" rid="fig2s8">Figure 2—figure supplement 8</xref>).</p><p>Collectively, these data demonstrate that the IRAK-dependent phosphorylation of Regnase-1 at S494 and S513 is necessary for the association between Regnase-1 and 14-3-3.</p></sec><sec id="s2-3"><title>βTRCP binds to 14-3-3-free Regnase-1</title><p>MyD88-dependent signaling also induces IKK-mediated phosphorylation of Regnase-1 at S435 and S439, which allows recognition of Regnase-1 by βTRCP (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>). With this, we examined the relationship between the association of Regnase-1 to 14-3-3 and to βTRCP. We found that Regnase-1 harboring S435A and S439A mutations permitted the interaction with 14-3-3 but failed to recruit βTRCP (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>). Reciprocally, the S494A or S513A mutation of Regnase-1 did not inhibit the association between Regnase-1 and βTRCP (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), indicating that the phosphorylation of Regnase-1 at S494 or S513 or the Regnase-1-14-3-3 binding is dispensable for the Regnase-1-βTRCP association. We next compared the phosphorylation status of βTRCP-bound and 14-3-3-bound Regnase-1. Since βTRCP-mediated polyubiquitination potentially alters the molecular weight of Regnase-1, we utilized a βTRCP mutant which is unable to induce polyubiquitination due to the lack of the F-box domain (βTRCP-ΔF). Interestingly, the SDS-PAGE analysis revealed that βTRCP-ΔF-bound Regnase-1 migrated faster than 14-3-3-bound Regnase-1 (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>), indicating that βTRCP likely binds to 14-3-3-free Regnase-1.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>βTRCP binds to 14-3-3-free Regnase-1.</title><p>(<bold>A</bold>) Immunoblot analysis of immunoprecipitates (IP: Myc) and WCL from HeLa cells transiently expressing Myc-14-3-3ε and HA-Regnase-1-WT or indicated mutants stimulated with IL-1β (10 ng/ml) for 4 hr. (<bold>B</bold>) Immunoblot analysis of immunoprecipitates (IP: FLAG) and WCL from HeLa cells transiently expressing FLAG-βTRCP1 and HA-Regnase-1-WT or indicated mutants stimulated with IL-1β (10 ng/ml) for 4 hr. (<bold>C</bold>) Immunoblot analysis of immunoprecipitates (IP: FLAG or HA) and WCL from HeLa cells transiently expressing FLAG-βTRCP-ΔF and HA-14-3-3ε stimulated with IL-1β (10 ng/ml) for 4 hr. S.E.: short exposure, L.E.: long exposure. (<bold>D</bold>) The intensity of Regnase-1-bands in (<bold>C</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig3-v3.tif"/></fig><p>These results demonstrate that the binding of Regnase-1 to 14-3-3 and βTRCP occurs independently although IL-1β stimulation simultaneously induces phosphorylation of Regnase-1 at S494 and S513 as well as S435 and S439. In addition, 14-3-3 inhibits the Regnase-1-βTRCP binding.</p></sec><sec id="s2-4"><title>The S513A mutation destabilizes Regnase-1 protein without affecting target mRNA abundance</title><p>To evaluate the functional roles of Regnase-1-14-3-3 interaction, we generated <italic>Zc3h12a</italic><sup>S513A/S513A</sup> knock-in mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). <italic>Zc3h12a</italic><sup>S513A/S513A</sup> mice did not show gross abnormality, nor did they exhibit alteration in the numbers of T, B cells or macrophages (data not shown). We stimulated mouse embryonic fibroblasts (MEFs) derived from <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> mice with IL-1β and checked Regnase-1 expression (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Immunoblot analysis revealed that Regnase-1 was degraded 30 min after stimulation in both WT and S513A mutant MEFs. Following this, Regnase-1 levels increased in WT MEFs at 2 and 4 hr after stimulation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Notably, most of the newly synthesized Regnase-1 showed slow migration, consistent with the immunoprecipitation experiment using HeLa cells or RAW264.7 cells shown in <xref ref-type="fig" rid="fig1">Figure 1C and D</xref>. On the other hand, the slowly migrating Regnase-1 band did not appear in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> MEFs after IL-1β stimulation. Interestingly, the amount of Regnase-1 at lower bands, which are not the binding target of 14-3-3 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), was comparable between WT and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> at corresponding time points. Consequently, total Regnase-1 protein expression was severely reduced in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> MEFs compared with WT after IL-1β stimulation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Similar results were also obtained when bone marrow-derived macrophages (BMDMs) and thioglycollate-elicited peritoneal exudate cells (PECs) derived from <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> mice were stimulated with LPS (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>). Nevertheless, <italic>Zc3h12a</italic> mRNA levels were comparable between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>), suggesting that S513A mutation affects the protein stability of Regnase-1. To address this, we examined the kinetics of Regnase-1 degradation following LPS stimulation by treating cells with cycloheximide (CHX). Indeed, Regnase-1-S513A was more rapidly degraded than Regnase-1-WT in PECs after LPS stimulation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Furthermore, treatment of <italic>Zc3h12a</italic><sup>S513A/S513A</sup> PECs with MG-132, a proteasome inhibitor, resulted in the increase of smearing in the band patterns of Regnase-1 in LPS-stimulated cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), possibly due to the inhibition of degradation of polyubiquitinated Regnase-1. These data indicate that the phosphorylation of Regnase-1 at S513 stabilizes Regnase-1 protein after IL-1β or LPS stimulation by binding with 14-3-3.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The S513A mutation destabilizes Regnase-1 protein but does not affect target mRNA abundance.</title><p>(<bold>A</bold>–<bold>C</bold>) Immunoblot analysis of <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> MEFs stimulated with IL-1β (10 ng/ml) (<bold>A</bold>), BMDMs stimulated with LPS (100 ng/ml) (<bold>B</bold>), and thioglycollate-elicited PECs stimulated with LPS (100 ng/ml) (<bold>C</bold>) for indicated time. PECs were pretreated with MG-132 (5 μM) 2 hr before the stimulation. (<bold>D</bold>)-(<bold>F</bold>) mRNA expression of <italic>Zc3h12a</italic> and <italic>Il6</italic> in <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> MEFs stimulated with IL-1β (10 ng/ml) for 4 hr (<bold>D</bold>), BMDMs stimulated with LPS (100 ng/ml) for 4 hr (<bold>E</bold>), and thioglycollate-elicited PECs stimulated with LPS (100 ng/ml) for indicated time (<bold>F</bold>). (<bold>G</bold>)-(<bold>I</bold>) IL-6 secretion in <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> MEFs stimulated with IL-1β (10 ng/ml), IL-17A (50 ng/ml), or TNF (10 ng/ml) for 24 hr (<bold>G</bold>), BMDMs stimulated with Pam<sub>3</sub>CSK<sub>4</sub> (1 or 10 ng/ml), poly I:C (10 or 100 μg/ml), LPS (10 or 100 ng/ml), R848 (10 or 100 nM), or CpG DNA (0.1 or 1 μM) for 24 hr (<bold>H</bold>), and thioglycollate-elicited PECs stimulated with LPS (100 ng/ml), R848 (100 nM), or IL-1β (10 ng/ml) for 24 hr (<bold>I</bold>). (<bold>J</bold>) Schematic representation of Model 1 in which 14-3-3-bound Regnase-1 does not have the function of degrading its target mRNAs. This model could explain the experimental observations. (<bold>K</bold>) Schematic representation of Model 2 in which 14-3-3-bound Regnase-1 maintains some ability to degrade its target mRNAs. This model is not consistent with the experimental observations. In (<bold>D</bold>)-(<bold>I</bold>), bars represent mean values of biological replicates (<italic>n</italic> = 3), and error bars represent standard deviation. Data is representative of two independent experiments, each with three biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Schematic illustration of <italic>Zc3h12a</italic> gene in mice.</title><p>The result of Sanger sequencing around S513 of Regnase-1 are shown below.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The protein stability of Regnase-1-WT and S513A.</title><p>Immunoblot analysis of <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> thioglycollate-elicited PECs treated with LPS (100 ng/ml) and CHX (100 μg/ml) for indicated time. CHX and LPS were added at the same time.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title><italic>Il6</italic> expression in <italic>Zc3h12a</italic><sup>–/–</sup> PECs mRNA expression of <italic>Il6</italic> and <italic>Zc3h12a</italic> in <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>–/–</sup> thioglycollate-elicited PECs stimulated with LPS (100 ng/ml) for indicated time.</title><p>Bars represent mean values of biological replicates (<italic>n</italic> = 3), and error bars represent standard deviation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig4-figsupp3-v3.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>The stability of Regnase-1 target mRNAs.</title><p>The remaining mRNA levels of indicated genes in <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> MEFs. Actinomycin D (ActD, 10 μg/ml) was added after 4 hr stimulation with IL-1β (10 ng/ml). Dots represent mean values of biological replicates (<italic>n</italic> = 3), and error bars represent standard deviation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig4-figsupp4-v3.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>S513A mutation of Regnase-1 does not affect gene expression.</title><p>Transcriptome analysis of <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> thioglycollate-elicited PECs stimulated with LPS (100 ng/ml) for indicated time. Several known Regnase-1 target transcripts are annotated. None of transcripts shows significant (adjusted p value &lt; 0.05) difference between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig4-figsupp5-v3.tif"/></fig></fig-group><p>We next checked whether the altered Regnase-1 expression by the S513A mutation affects Regnase-1-mediated mRNA decay. Despite the huge difference in Regnase-1 expression, the expression of <italic>Il6</italic>, a transcript degraded by Regnase-1 (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), was comparable between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells (<xref ref-type="fig" rid="fig4">Figure 4D–I</xref>). In addition, the stability of Regnase-1 target mRNAs including <italic>Il6</italic>, <italic>Zc3h12a</italic>, and <italic>Nfkbiz</italic> was equivalent between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Furthermore, even when we analyzed gene expression profile comparing <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> macrophages by an RNA-seq analysis (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>), we did not identify any differentially expressed genes (adj p&lt;0.05) between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> macrophages irrespective of the stimulation with LPS.</p><p>To examine the mechanisms underlying these observations, we developed two mathematical models based on our previous studies (see Materials and methods) (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>; <xref ref-type="bibr" rid="bib31">Mino et al., 2019</xref>). The first model (Model 1) assumes that 14-3-3-bound Regnase-1 is unable to degrade its target mRNAs (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). The second model (Model 2) assumes that Regnase-1 binding with 14-3-3 maintains its ability to degrade its target mRNAs to a certain extent (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). Mathematical analysis showed that in Model 2, the abundance of the <italic>Il6</italic> mRNAs should be different between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells under the condition that the amount of 14-3-3-free Regnase-1 protein (lower bands in <xref ref-type="fig" rid="fig4">Figure 4A–C</xref>) is comparable between them. Our observations that the abundance of the target mRNAs did not differ between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells in the late phase of stimulation is inconsistent with Model 2, suggesting that Regnase-1 is inactivated upon binding to 14-3-3.</p><p>These results imply that the phosphorylation at S513 and the following association with 14-3-3 nullifies Regnase-1’s ability in degrading target mRNAs, although it stabilizes and significantly upregulates the abundance of Regnase-1.</p></sec><sec id="s2-5"><title>14-3-3 inactivates Regnase-1 by inhibiting Regnase-1-RNA binding</title><p>The mathematical analysis suggests that 14-3-3-bound Regnase-1 is inactive as the S513A mutation failed to affect <italic>Il6</italic> expression in MEFs or macrophages. To examine if this comparable <italic>Il6</italic> expression was due to increased degradation of Regnase-1-S513A protein via βTRCP, we further mutated βTRCP-recognition sites, S435 and S439, to alanine in Regnase-1-S513A (Regnase-1-S435/439/513A). As shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>, the Regnase-1-S435/439/513A mutant was more abundantly expressed than Regnase-1-S513A after IL-1β stimulation, indicating that Regnase-1-S513A is degraded via the association with βTRCP. It is noteworthy that most of Regnase-1-S435/439/513A showed fast migration, whereas the majority of Regnase-1-S435/439A migrated slowly in response to the stimulation. To verify if 14-3-3-bound Regnase-1 is functional or not, we assessed the target mRNA suppression activity of each mutant by checking the expression of <italic>Il6</italic> co-transfected with Regnase-1. Regnase-1-S435/439/513A was more potent in suppressing <italic>Il6</italic> expression compared to WT or other SA mutants, S513A and S435/439A, in response to IL-1β stimulation (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These results indicate that IL-1β stimulation regulates the activity of Regnase-1 by two independent mechanisms via 14-3-3 and βTRCP, respectively.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>14-3-3 bound to phospho-S494 and S513 inactivates Regnase-1 by inhibiting Regnase-1-mRNA binding.</title><p>(<bold>A</bold>) Immunoblot analysis of <italic>ZC3H12A</italic>-KO HeLa cells transiently expressing Regnase-1-WT or indicated mutants. Cells were stimulated with IL-1β (10 ng/ml) for indicated time. (<bold>B</bold>) mRNA expression of <italic>Il6</italic> in HeLa cells transiently expressing Regnase-1-WT or indicated mutants together with <italic>Il6</italic>. Cells were stimulated with IL-1β (10 ng/ml) for indicated time. (<bold>C</bold>) Immunoblot analysis of immunoprecipitates (IP: FLAG) and WCL from HeLa cells transiently expressing FLAG-Regnase-1-WT or indicated mutants. For the IL-1β stimulation, cells were stimulated with IL-1β (10 ng/ml) for 4 hr. L.C.: light chain. (<bold>D</bold>) Schematic illustration of Regnase-1 and the amino acid sequences of Regnase-1-WT, -ExoSx2, and ExoSAAAx2. NTD: N-terminal domain, ZF: Zinc finger domain, CTD: C-terminal domain. (<bold>E</bold>) mRNA expression of <italic>Il6</italic> in HeLa cells transiently expressing Regnase-1-WT or indicated mutants together with <italic>Il6</italic>. (<bold>F</bold>) Secreted IL6 concentration in (<bold>E</bold>). (<bold>G</bold>) mRNA expression of <italic>Il6</italic> in HeLa cells transiently expressing Regnase-1-WT and IRAK1-WT or indicated mutants together with <italic>Il6</italic>. (<bold>H</bold>) The amount of <italic>IL6</italic> mRNAs immunoprecipitated with FLAG-Regnase-1-D141N or other indicated mutants in HeLa cells. In (<bold>B</bold>), (<bold>E</bold>)-(<bold>H</bold>), bars represent mean values of biological replicates (<italic>n</italic> = 3), and error bars represent standard deviation. p-Values were calculated using unpaired, two-sided t-test. Data is representative of two independent experiments, each with three biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Regnase-1-ExoSx2-D141N binds to 14-3-3.</title><p>Immunoblot analysis of immunoprecipitates (IP: FLAG) and WCL from HeLa cells transiently expressing FLAG-Regnase-1-D141N or indicated mutants. L.C.: light chain.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Regnase-1-ExoSx2-D141N failed to bind to target mRNAs.</title><p>The amount of mRNAs immunoprecipitated with FLAG-Regnase-1-D141N or other indicated mutants in HeLa cells. The binding targets of Regnase-1 are denoted with *. Bars represent mean values of biological replicates (n=3), and error bars represent standard deviation. p-Values were calculated using unpaired, two-sided t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig5-figsupp2-v3.tif"/></fig></fig-group><p>To further examine the mechanism of how 14-3-3 inactivates Regnase-1, we attempted to generate a Regnase-1 mutant which constitutively binds to 14-3-3 even without stimulation. We generated a phospho-mimic mutant of Regnase-1 (S494D/S513D). However, this mutant failed to bind 14-3-3 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), indicating that the phosphate moiety, but not negative charge, is recognized by 14-3-3. Then we utilized a sequence of Exoenzyme S (ExoS), which is a bacterial protein derived from <italic>Pseudomonas aeruginosa</italic> and is known to bind to 14-3-3 without phosphorylation (<xref ref-type="bibr" rid="bib12">Fu et al., 1993</xref>; <xref ref-type="bibr" rid="bib22">Karlberg et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Masters et al., 1999</xref>). The 22 amino acids of Regnase-1 covering S494 and S513 were substituted with two ExoS (419-429) sequences (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). As a control, we additionally mutated Regnase-1-ExoSx2 by substituting its core sequences for 14-3-3 binding (L426, D427, and L428) with alanine residues (Regnase-1-ExoSAAAx2) (<xref ref-type="bibr" rid="bib39">Ottmann et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Yasmin et al., 2006</xref>). We observed that Regnase-1-ExoSx2, but not Regnase-1-ExoSAAAx2, interacted with endogenous 14-3-3 without any stimulation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Using these mutants, we investigated whether 14-3-3 binding alters the activity of Regnase-1 to suppress <italic>Il6</italic> expression. Consistent with its 14-3-3 binding capacity, Regnase-1-ExoSx2, but not Regnase-1-ExoSAAAx2 and -S494D/S513D, lost the activity to inhibit <italic>Il6</italic> expression (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Furthermore, the production of IL-6 protein was similarly inhibited depending on the capacity of Regnase-1 to bind 14-3-3 (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). In addition, Regnase-1-mediated suppression of <italic>Il6</italic> expression was impaired by the overexpression of IRAK1-WT and E541/E584/E704A mutants, both of which induce Regnase-1-14-3-3 association (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). On the other hand, IRAK1 mutants that failed to induce the Regnase-1-14-3-3 association (T209A, Δ1–103, Δ619–710, and R663/K665A) did not affect the activity of Regnase-1.</p><p>We next examined how 14-3-3 inhibits the activity of Regnase-1 by investigating Regnase-1-mRNA binding activity using various Regnase-1 mutants in HeLa cells. To stabilize Regnase-1-RNA binding, we generated a nuclease inactive version of Regnase-1 by introducing the D141N mutation to each of Regnase-1 mutant (<xref ref-type="bibr" rid="bib28">Matsushita et al., 2009</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). As shown in <xref ref-type="fig" rid="fig5">Figure 5H</xref>, forced interaction of Regnase-1-D141N with 14-3-3 by the ExoSx2 mutation in HeLa cells abrogated the binding with <italic>IL6</italic> mRNA, whereas <italic>IL6</italic> was co-precipitated with Regnase-1-D141N, -ExoSAAAx2-D141N and -S494D/S513D-D141N (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). In addition to <italic>IL6</italic>, Regnase-1-ExoSx2 failed to bind to other reported target mRNAs such as <italic>NFKBIZ</italic>, <italic>PTGS2</italic>, and CXC chemokines (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Collectively, these data demonstrate that 14-3-3 inhibits Regnase-1-mRNA binding, thereby abrogating Regnase-1-mediated mRNA degradation.</p></sec><sec id="s2-6"><title>14-3-3 inhibits nuclear import of Regnase-1</title><p>We have previously shown that Regnase-1 interacts with CBP80-bound, but not eIF4E-bound, mRNAs (<xref ref-type="bibr" rid="bib31">Mino et al., 2019</xref>), indicating that Regnase-1 degrades mRNAs immediately after the export from the nucleus to the cytoplasm (<xref ref-type="bibr" rid="bib26">Maquat et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Müller-McNicoll and Neugebauer, 2013</xref>). Although Regnase-1 mainly localizes in the cytoplasm (<xref ref-type="bibr" rid="bib30">Mino et al., 2015</xref>), we hypothesized Regnase-1 shuttles between the nucleus and the cytoplasm to recognize its target mRNAs in association with their nuclear export. To test this hypothesis, we examined the subcellular localization of Regnase-1 following the treatment with Leptomycin B (LMB), which inhibits CRM1 (also known as Exportin-1)-mediated protein export from the nucleus to the cytoplasm (<xref ref-type="bibr" rid="bib59">Yashiroda and Yoshida, 2003</xref>). Although Regnase-1 localized in the cytoplasm in the steady state condition, LMB treatment induced rapid accumulation of Regnase-1 in the nucleus within 30 min (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). These results suggest that Regnase-1 dynamically changes its localization between the cytoplasm and the nucleus. Given that Regnase-1 dominantly localizes in the cytoplasm in the steady state conditions, the frequency of its nuclear export seems to be higher than its nuclear import.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>14-3-3 inhibit nuclear-cytoplasmic shuttling of Regnase-1.</title><p>(<bold>A</bold>) Immunofluorescence analysis of HeLa cells transiently expressing FLAG-Regnase-1-WT treated with Leptomycin B (LMB) (10 ng/ml) for indicated time. (<bold>B</bold>) The result of NES prediction of Regnase-1 by LocNES. Higher score indicates higher probability. (<bold>C</bold>) Schematic illustration of Regnase-1. The amino acid sequence shown in (<bold>D</bold>) is highlighted in blue. NTD: N-terminal domain, ZF: Zinc finger domain, CTD: C-terminal domain. (<bold>D</bold>) The amino acid sequences including S435/S439 and NES of Regnase-1 from mouse and other indicated vertebrates. (<bold>E</bold>) Immunofluorescence analysis of HeLa cells transiently expressing FLAG-Regnase-1-WT or indicated mutants. (<bold>F</bold>) Immunofluorescence analysis of HeLa cells transiently expressing FLAG-Regnase-1-WT or indicated mutants treated with LMB (10 ng/ml) for 1 hr. (<bold>G</bold>) Model of 14-3-3- and βTRCP-mediated regulation of Regnase-1. In the steady state, Regnase-1 shuttles between the nucleus and the cytoplasm and degrades target mRNAs such as <italic>Il6</italic>. Under IL-1β or TLR-ligands stimulation, two different regulatory mechanisms suppress the activity of Regnase-1 not to disturb proper expression of inflammatory genes; βTRCP induces protein degradation of Regnase-1 and 14-3-3 inhibits nuclear-cytoplasmic shuttling and mRNA recognition of Regnase-1. In (<bold>A</bold>), (<bold>E</bold>), and (<bold>F</bold>), white scale bars indicate 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71966-fig6-v3.tif"/></fig><p>CRM1 is known to recognize a nuclear export signal (NES) of a cargo protein for the protein export (<xref ref-type="bibr" rid="bib18">Hutten and Kehlenbach, 2007</xref>). Thus, we investigated if Regnase-1 harbors a NES. In silico prediction deduced amino acids 433–447 of Regnase-1 as a potential NES with high probability (<xref ref-type="bibr" rid="bib56">Xu et al., 2015</xref>; <xref ref-type="fig" rid="fig6">Figure 6B–D</xref>). Indeed, Regnase-1 lacking 422–451 spontaneously accumulated in the nucleus (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Since NESs are characterized by hydrophobic residues (<xref ref-type="bibr" rid="bib24">la Cour et al., 2003</xref>), we also inspected which hydrophobic resides of Regnase-1 were important for the efficient nuclear export of Regnase-1. We found that L440, M444, L447, and W448 of Regnase-1 were critical for the nuclear export of Regnase-1 (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Noteworthy, all the residues are highly conserved among species (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>We next examined whether 14-3-3 binding controls the localization of Regnase-1. Interestingly, Regnase-1-ExoSx2 failed to accumulate in the nucleus even after LMB treatment while Regnase-1-WT and -ExoSAAAx2 accumulated in the nucleus by LMB treatment (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). This result indicates that Regnase-1-ExoSx2 is unable to translocate into the nucleus like Regnase-1-WT. Taken together, 14-3-3 inhibits the nuclear import of Regnase-1 as well as its binding to target mRNAs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we discovered that IL-1β and TLR stimulation dynamically changes protein-protein interaction of Regnase-1. Particularly, these stimuli trigger the interaction of Regnase-1 with 14-3-3 as well as βTRCP via phosphorylation at distinct amino acids. Whereas phosphorylation of Regnase-1 at S494 and S513 is recognized by 14-3-3, βTRCP associates with Regnase-1 phosphorylated at S435 and S439. We demonstrated that each Regnase-1-14-3-3 and Regnase-1-βTRCP binding occurs independently. Furthermore, 14-3-3 prevent Regnase-1-βTRCP binding, resulting in protein stabilization of 14-3-3-bound Regnase-1.</p><p>The amino acid sequence surrounding S494 and S513 of Regnase-1 is widely conserved among species. Particularly, both S494 and S513 harbor the pSxP sequence motif, which overlaps with a known 14-3-3 binding motif, RxxpSxP, mode 1 (<xref ref-type="bibr" rid="bib57">Yaffe et al., 1997</xref>). It is quite plausible that the 14-3-3 dimer directly binds to phosphorylated S494 and S513 of Regnase-1 with the phospho-peptide binding groove. Interestingly, only 14-3-3σ, which forms a homodimer but not a heterodimer with other 14-3-3 isoforms (<xref ref-type="bibr" rid="bib51">Verdoodt et al., 2006</xref>), failed to bind with Regnase-1 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). This result might be a clue to elucidate the target specificity of each 14-3-3 paralog.</p><p>14-3-3 and βTRCP inhibit Regnase-1-mediated mRNA decay via distinct mechanisms; 14-3-3 prevents Regnase-1-mRNA binding while βTRCP induces protein degradation of Regnase-1. Analysis of <italic>Zc3h12a</italic><sup>S513A/S513A</sup> mice revealed that 14-3-3-mediated abrogation of Regnase-1 can be compensated by the degradation of Regnase-1. The presence of this dual regulatory system underscores the importance of restricting the activity of Regnase-1 to ensure proper inflammatory gene expression when cells encounter PAMPs or DAMPs (<xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p><p>Notably, exome sequence analysis of the colon samples from ulcerative colitis patients discovered mutations in the βTRCP binding site of Regnase-1 (<xref ref-type="bibr" rid="bib21">Kakiuchi et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Nanki et al., 2020</xref>). Furthermore, a previous report showed that <italic>Zc3h12a</italic><sup>S435/S439A</sup> mutant mice were resistant to experimental autoimmune encephalomyelitis (EAE) (<xref ref-type="bibr" rid="bib47">Tanaka et al., 2019</xref>). All these mutations abolish βTRCP-mediated degradation of Regnase-1. However, genetic association between the 14-3-3-binding site of Regnase-1 and inflammatory diseases has not been identified so far. This is possibly because of the compensation by βTRCP-mediated regulation, which we observed in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> mice and HeLa cells transiently expressing Regnase-1-S513A and S435/439/513A. Previous studies have shown that viral proteins or lncRNAs inhibit βTRCP-mediated protein degradation (<xref ref-type="bibr" rid="bib15">Guo et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Neidel et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">van Buuren et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Yang et al., 2020</xref>). 14-3-3-mediated regulation of Regnase-1 may serve as a backup mechanism to control the activity of Regnase-1 when βTRCP-mediated protein degradation is dysregulated.</p><p>While βTRCP regulates the abundance of Regnase-1 through protein degradation, 14-3-3 regulates the activity of Regnase-1. We found that 14-3-3-bound Regnase-1 failed to associate with mRNAs, indicating that 14-3-3 prevents Regnase-1 from recognizing target mRNA. We have previously shown that an RNase domain and an adjacent zinc finger domain play an important role in Regnase-1-RNA binding (<xref ref-type="bibr" rid="bib62">Yokogawa et al., 2016</xref>). However, the 14-3-3-binding site of Regnase-1 is in the C-terminal part of Regnase-1, which is distant from RNase and zinc finger domains. Therefore, 14-3-3 is unlikely to inhibit Regnase-1-mRNA binding by simple competition between 14-3-3 and mRNAs for the RNA binding domain of Regnase-1. We have previously reported that Regnase-1 interacts with CBP80-bound, but not eIF4E-bound, mRNAs, indicating that Regnase-1 recognizes its target mRNA before or immediately after the nuclear export of the mRNA (<xref ref-type="bibr" rid="bib31">Mino et al., 2019</xref>). In this study, we found that Regnase-1 shuttles between the nucleus and the cytoplasm while 14-3-3-bound Regnase-1 cannot enter the nucleus. Thus, it is tempting to speculate that Regnase-1 recognizes mRNA in the nucleus and induce mRNA decay during pioneer rounds of translation immediately after the nuclear export (<xref ref-type="bibr" rid="bib26">Maquat et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Müller-McNicoll and Neugebauer, 2013</xref>). Nevertheless, further investigation is required to clarify the mechanisms of Regnase-1-mediated mRNA decay depending on its nuclear-cytoplasmic shuttling. In addition, further studies are also necessary to clarify the molecular mechanisms how 14-3-3 controls the nuclear-cytoplasmic shuttling of Regnase-1 as well as how it regulates Regnase-1-mRNA binding by exploiting systems beyond the ExoS sequence-mediated interaction with 14-3-3.</p><p>βTRCP is likely to recognize 14-3-3-free Regnase-1, indicating that 14-3-3 inhibits Regnase-1-βTRCP interaction. There are two possible mechanisms to explain this. One posits that 14-3-3 bound to phosphorylated S494 and S513 of Regnase-1 conceals βTRCP-binding site (pS435 and pS439), although the 14-3-3-binding site does not overlap with βTRCP-binding site completely. The other possible explanation is that 14-3-3-mediated inhibition of nuclear-cytoplasmic shuttling of Regnase-1 controls βTRCP-mediated Regnase-1 degradation. Indeed, βTRCP localizes not only in the cytoplasm, but also in the nucleus (<xref ref-type="bibr" rid="bib9">Davis et al., 2002</xref>). It is plausible that 14-3-3 prevents Regnase-1-βTRCP interaction in the nucleus, by inhibiting nuclear-cytoplasmic shuttling of Regnase-1. Of note, the NES of Regnase-1 is located just adjacent to βTRCP-binding site (<xref ref-type="fig" rid="fig6">Figure 6C–D</xref>), implying possibility of competitive binding of βTRCP and CRM1 to Regnase-1.</p><p>Among the molecules involved in MyD88-dependent signaling, we found that IRAK1/2 are potent inducers of the interaction between Regnase-1 and 14-3-3, thereby abrogating Regnase-1-mediated mRNA decay. We also found that kinase-inactive IRAK1 failed to induce the Regnase-1-14-3-3 complex, suggesting that the kinase activity of IRAK1 is required for the phosphorylation of Regnase-1 at S494 and S513. However, previously identified substrate sequence motifs of IRAK1, pSxV, and KxxxpS (<xref ref-type="bibr" rid="bib44">Sugiyama et al., 2019</xref>) do not match the sequence surrounding S494 and S513 of Regnase-1 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Although the motif analysis does not exclude the possibility of direct phosphorylation of Regnase-1 by IRAK1, it is possible that kinases activated by IRAK1/2 phosphorylates Regnase-1 at S494 and S513.</p><p>IRAKs are involved in stabilization of inflammatory mRNAs as well as NF-κB activation (<xref ref-type="bibr" rid="bib11">Flannery et al., 2011</xref>; <xref ref-type="bibr" rid="bib17">Hartupee et al., 2008</xref>; <xref ref-type="bibr" rid="bib52">Wan et al., 2009</xref>). A previous study showed that IRAK1-mediated mRNA stabilization does not require IRAK1-TRAF6 association (<xref ref-type="bibr" rid="bib17">Hartupee et al., 2008</xref>). Interestingly, the IRAK1-TRAF6 association is also dispensable for the Regnase-1-14-3-3 binding. Instead, other evolutionarily conserved amino acids in the C-terminal structural domain (CSD) of IRAK1, R663, and K665, are critical for Regnase-1-14-3-3 binding. Considering 14-3-3-mediated inactivation of Regnase-1, it is plausible that the CSD of IRAK1 is the key for stabilization of inflammatory mRNAs.</p><p>In summary, Regnase-1 interactome analysis revealed dynamic 14-3-3-mediated regulation of Regnase-1 in response to IL-1β and TLR stimuli. Since recent studies identified Regnase-1 as a high-potential therapeutic target in various diseases (<xref ref-type="bibr" rid="bib21">Kakiuchi et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Nanki et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Wei et al., 2019</xref>), our findings may help maximize the effect of Regnase-1 modulation or provide an alternative way to control the activity of Regnase-1.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>Mus musculus</italic>)</td><td><italic>Zc3h12a</italic></td><td>NA</td><td>Gene ID: 230738</td><td/></tr><tr><td>Gene (<italic>Homo sapiens</italic>)</td><td><italic>ZC3H12A</italic></td><td>NA</td><td>Gene ID: 80149</td><td/></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td><italic>Zc3h12a</italic><sup>WT/WT</sup></td><td>CLEA Japan</td><td>C57BL/6</td><td>C57BL/6JJcl</td></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td><italic>Zc3h12a</italic><sup>-/-</sup></td><td><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature07924">https://doi.org/10.1038/nature07924</ext-link></td><td/><td/></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td><italic>Zc3h12a</italic><sup>S513A/S513A</sup></td><td>this paper</td><td/><td>generated using CRISPR-Cas9 system</td></tr><tr><td>Sequence-based reagent</td><td>DNA oligo (for pX330)</td><td>this paper</td><td>CACCGCGGCTCAGACCAGTACTCTC</td><td>for <italic>Zc3h12a</italic><sup>S513A/S513A</sup> generation</td></tr><tr><td>Sequence-based reagent</td><td>DNA oligo (for pX330)</td><td>this paper</td><td>AAACGAGAGTACTGGTCTGAGCCGC</td><td>for <italic>Zc3h12a</italic><sup>S513A/S513A</sup> generation</td></tr><tr><td>Sequence-based reagent</td><td>Donor single strand oligo</td><td>this paper</td><td>GAAGGACAGGAGTGGGTGGGGGTAATGGGTACGGCTCAGCCCAGTACTCTCTGGATGGGTAGGTGGGTGGCGGGGGCACA</td><td>for <italic>Zc3h12a</italic><sup>S513A/S513A</sup> generation</td></tr><tr><td>Sequence-based reagent</td><td>DNA oligo (for pX459-<italic>IRAK1</italic>KO)</td><td><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btu743">https://doi.org/10.1093/bioinformatics/btu743</ext-link></td><td>CACCGGTCTGGTCGCGCACGATCA</td><td/></tr><tr><td>Sequence-based reagent</td><td>DNA oligo (for pX459-<italic>IRAK1</italic>KO)</td><td><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btu743">https://doi.org/10.1093/bioinformatics/btu743</ext-link></td><td>AAACTGATCGTGCGCGACCAGACC</td><td/></tr><tr><td>Sequence-based reagent</td><td>DNA oligo (for pX459-<italic>IRAK2</italic>KO)</td><td><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.3437">https://doi.org/10.1038/nbt.3437</ext-link></td><td>CACCGAAAACCGCAAAATCAGCCAG</td><td/></tr><tr><td>Sequence-based reagent</td><td>DNA oligo (for pX459-<italic>IRAK2</italic>KO)</td><td><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.3437">https://doi.org/10.1038/nbt.3437</ext-link></td><td>AAACCTGGCTGATTTTGCGGTTTTC</td><td/></tr><tr><td>Antibody</td><td>Anti-mouse-Regnase-1 <break/>(rabbit polyclonal)</td><td>MBL life science</td><td/><td>custom antibody production <break/>(1:1000)</td></tr><tr><td>Antibody</td><td>Anti-human-Regnase-1 <break/>(rabbit polyclonal)</td><td>Atlas Antibodies</td><td>Cat # HPA032053</td><td>(1:500)</td></tr><tr><td>Antibody</td><td>Anti-14-3-3 (pan) <break/>(mouse monoclonal)</td><td>Santa Cruz Biotechnology</td><td>Cat # sc-1657</td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Anti-IκB-α <break/>(rabbit polyclonal)</td><td>Santa Cruz Biotechnology</td><td>Cat # sc-371</td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Anti-IRAK1 <break/>(mouse monoclonal)</td><td>Santa Cruz Biotechnology</td><td>Cat # sc-5288</td><td>(1:500)</td></tr><tr><td>Antibody</td><td>Anti-FLAG <break/>(mouse monoclonal)</td><td>Sigma</td><td>Cat # F3165</td><td>(WB:1:2000, IF:1:5000)</td></tr><tr><td>Antibody</td><td>Anti-FLAG <break/>(rabbit polyclonal)</td><td>Sigma</td><td>Cat # F7425</td><td>(1:2000)</td></tr><tr><td>Antibody</td><td>Anti-HA <break/>(mouse monoclonal)</td><td>Sigma</td><td>Cat # H3663</td><td>(1:2000)</td></tr><tr><td>Antibody</td><td>Anti-HA <break/>(rabbit polyclonal)</td><td>Sigma</td><td>Cat # H6908</td><td>(1:2000)</td></tr><tr><td>Antibody</td><td>Anit-Myc <break/>(mouse monoclonal)</td><td>Sigma</td><td>Cat # M4439</td><td>(1:2000)</td></tr><tr><td>Antibody</td><td>Anti-Myc <break/>(rabbit polyclonal)</td><td>Sigma</td><td>Cat # C3956</td><td>(1:2000)</td></tr><tr><td>Antibody</td><td>Anti-β-Actin-HRP <break/>(mouse monoclonal)</td><td>Santa Cruz Biotechnology</td><td>Cat # sc-47778-HRP</td><td>(1:2000)</td></tr><tr><td>Antibody</td><td>Anti-Mouse IgG-HRP F(ab')2 <break/>(sheep polyclonal)</td><td>cytiva</td><td>Cat # NA9310-1ML</td><td>(1:5000)</td></tr><tr><td>Antibody</td><td>Anti-Rabbit IgG-HRP F(ab')2 <break/>(donkey polyclonal)</td><td>cytiva</td><td>Cat # NA9340-1ML</td><td>(1:5000)</td></tr><tr><td>Antibody</td><td>F(ab')2-anti-Mouse IgG (H+L)-AF488 <break/>(Goat polyclonal)</td><td>Invitrogen</td><td>Cat # A11017</td><td>(1:2000)</td></tr><tr><td>Recombinant DNA reagent</td><td>pX330-U6-Chimeric_BB-CBh-hSpCas9</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_42230">Addgene_42230</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pSpCas9(BB)-2A-Puro (PX459) V2.0</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_62988">Addgene_62988</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pMD2.G</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12259">Addgene_12259</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pMDLg/pRRE</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12251">Addgene_12251</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pRSV-Rev</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12253">Addgene_12253</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pInducer20</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_44012">Addgene_44012</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pInducer20-puro</td><td>this paper</td><td/><td>NeoR of pInducer20 (Addgene_44012) was replaced with PuroR</td></tr><tr><td>Recombinant DNA reagent</td><td>pFLAG-CMV2</td><td>Sigma</td><td>Cat # E7033</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pEGFP-C1</td><td>Clontech</td><td/><td/></tr><tr><td>Peptide, recombinant protein</td><td>FLAG Peptide</td><td>Sigma</td><td>Cat # F3290</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>HA peptide</td><td>MBL Life science</td><td>Cat # 3320</td><td>HA tagged Protein PURIFICATION KIT</td></tr><tr><td>Peptide, recombinant protein</td><td>recombinant human IL-1β</td><td>R and D Systems</td><td>Cat # 201-LB-005</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>recombinant mouse IL-1β</td><td>BioLegend</td><td>Cat # 575102</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>recombinant human IL-17A</td><td>BioLegend</td><td>Cat # 570502</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>recombinant human TNF</td><td>BioLegend</td><td>Cat # 570104</td><td/></tr><tr><td>Commercial assay or kit</td><td>Dynabeads Protein G</td><td>Invitrogen</td><td>Cat # 10004D</td><td/></tr><tr><td>Commercial assay or kit</td><td>Lambda Protein Phosphatase</td><td>NEB</td><td>Cat # P0753S</td><td/></tr><tr><td>Commercial assay or kit</td><td>Signal Enhancer HIKARI</td><td>nacalai tesque</td><td>Cat # 02270-81</td><td/></tr><tr><td>Commercial assay or kit</td><td>Immobilon Forte Western HRP Substrate</td><td>Millipore</td><td>Cat # WBLUF0500</td><td/></tr><tr><td>Commercial assay or kit</td><td>TRIzol Reagent</td><td>Invitrogen</td><td>Cat # 15596018</td><td/></tr><tr><td>Commercial assay or kit</td><td>RNA Clean and Concentrator-5</td><td>Zymo Research</td><td>Cat # R1014</td><td/></tr><tr><td>Commercial assay or kit</td><td>PowerUp SYBR Green Master Mix</td><td>Applied Biosystems</td><td>Cat # A25742</td><td/></tr><tr><td>Commercial assay or kit</td><td>IL-6 Mouse Uncoated ELISA Kit</td><td>Invitrogen</td><td>Cat # 88-7064-88</td><td/></tr><tr><td>Chemical compound, drug</td><td>DSP (dithiobis(succinimidyl propionate))</td><td>TCI</td><td>Cat # D2473</td><td/></tr><tr><td>Chemical compound, drug</td><td>Pam3CSK4</td><td>InvivoGen</td><td>Cat # tlrl-pms</td><td/></tr><tr><td>Chemical compound, drug</td><td>poly I:C</td><td>cytiva</td><td>Cat # 27473201</td><td/></tr><tr><td>Chemical compound, drug</td><td>LPS</td><td>InvivoGen</td><td>Cat # tlrl-smlps</td><td/></tr><tr><td>Chemical compound, drug</td><td>R848</td><td>InvivoGen</td><td>Cat # tlrl-r848-5</td><td/></tr><tr><td>Chemical compound, drug</td><td>CpG DNA</td><td>InvivoGen</td><td>Cat # tlrl-1668-1</td><td>ODN 1668</td></tr><tr><td>Chemical compound, drug</td><td>MG-132</td><td>Sigma</td><td>Cat # 474790</td><td/></tr><tr><td>Chemical compound, drug</td><td>Actinomycin D</td><td>Sigma</td><td>Cat # A9415</td><td/></tr><tr><td>Chemical compound, drug</td><td>Leptomycin B</td><td>Sigma</td><td>Cat # L2913</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p><italic>Zc3h12a</italic>-deficient mice have been described previously (<xref ref-type="bibr" rid="bib28">Matsushita et al., 2009</xref>). <italic>Zc3h12a</italic><sup>S513A/S513A</sup> knock-in mice were generated using CRISPR/Cas9-mediated genome-editing technology as previously described (<xref ref-type="bibr" rid="bib13">Fujihara and Ikawa, 2014</xref>). Briefly, a pair of complementary DNA oligos was annealed and inserted into pX330 (Addgene plasmid # 42230) (<xref ref-type="bibr" rid="bib7">Cong et al., 2013</xref>). The plasmid was injected together with the donor single strand oligo into fertilized eggs of C57BL/6J mice. Successful insertion was confirmed by direct sequencing.</p><p>All mice were grown under specific pathogen-free environments. All animal experiments were conducted in compliance with the guidelines of the Kyoto University animal experimentation committee (Approval number: MedKyo21057).</p></sec><sec id="s4-2"><title>Reagents</title><p>Recombinant cytokines, TLR ligands, and chemical compounds were listed in the key resources table.</p></sec><sec id="s4-3"><title>Cell culture</title><p>HeLa cells, HEK293T cells, RAW264.7 cells, and MEFs were maintained in DMEM (nacalai tesque) with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin (nacalai tesque), and 100 µM 2-Mercaptoethanol (nacalai tesque). Mycoplasma contamination was routinely tested and found negative.</p><p>For the preparation of bone marrow-derived macrophages (BMDMs), bone marrow cells were cultured in RPMI-1640 (nacalai tesque) with 10% FBS, 1% Penicillin/Streptomycin, 100 μM 2-mercaptoethanol, and 20 ng/ml of macrophage colony-stimulating factor (M-CSF) (BioLegend) for 6 days.</p><p>For the preparation of thioglycolate-elicited peritoneal exudate cells (PECs), mice were intraperitoneally injected with 2 ml of 4% (w/v) Brewer’s thioglycollate medium. 3.5 days after the injection, peritoneal macrophages were collected and cultured in RPMI-1640 with 10% FBS, 1% Penicillin/Streptomycin, and 100 μM 2-mercaptoethanol.</p></sec><sec id="s4-4"><title>Plasmids</title><p>For the expression of FLAG-tagged proteins, pFLAG-CMV2 (Sigma) was used as a backbone. For the expression of HA- or Myc-tagged proteins, the FLAG sequence of pFLAG-CMV2 was replaced by HA- or Myc-sequence. Mouse <italic>Zc3h12a</italic> cDNA was inserted into these vectors as previously described (<xref ref-type="bibr" rid="bib28">Matsushita et al., 2009</xref>). The coding sequences of 14-3-3 and βTRCP were amplified by using cDNAs derived from HeLa cell as templates and inserted into vectors above using In-Fusion HD Cloning Kit (Takara Bio). For Myc-IRAK1 expression vector, coding sequence of IRAK1 derived from HA-IRAK1 expression vector (<xref ref-type="bibr" rid="bib19">Iwasaki et al., 2011</xref>) was used. For the mouse <italic>Il6</italic> expression vector, the EGFP sequence in pEGFP-C1 was replaced with <italic>Il6</italic> gene.</p><p>Deletions or point mutations were introduced using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) or In-Fusion HD Cloning Kit.</p><p>For the lentiviral packaging vectors, pInducer20 (Addgene plasmid #44012) (<xref ref-type="bibr" rid="bib29">Meerbrey et al., 2011</xref>) was modified to generate pInducer20-puro. FLAG-HA-Regnase-1 sequence was inserted into pInducer20-puro using In-Fusion HD Cloning Kit.</p><p>For the Cas9 and gRNA expression plasmids (pX459-IRAK1 and pX459-IRAK2), pX459 (Addgene Plasmid #62988) was digested at BbsI sites, and the annealed oligo coding guide sequence (key resources table) was inserted.</p></sec><sec id="s4-5"><title>Plasmid transfection</title><p>Plasmids were transfected to HeLa cells or HEK293T cells using Lipofectamine 2000 (Invitrogen) or PEI max (Polysciences) respectively according to manufacturer's instructions.</p></sec><sec id="s4-6"><title>Generation of doxycycline-inducible FLAG-HA-Regnase-1-expressing HeLa cells</title><p>HeLa cells expressing FLAG-HA-Regnase-1 in a doxycycline-dependent manner were generated by lentiviral transduction. To produce lentivirus, HEK293T cells were transfected with pInducer20-puro-FLAG-HA-Regnase1 together with third generation lentiviral packaging vectors. 6 hr after the transfection, the medium was changed to fresh medium and then the cells were incubated at 37°C for 48 hr. After the incubation, the medium containing lentivirus was harvested and filtrated through 0.45 μm filter. HeLa cells were incubated with the virus-containing medium at 37°C for 24 hr, followed by 48-hr-incubation with fresh medium. The transduced cells were selected by 0.5 μg/ml of puromycin (InvivoGen). Single clones were picked and evaluated for their expression of FLAG-HA-Regnase-1 in a dox-dependent manner by immunoblotting.</p></sec><sec id="s4-7"><title>Knockout of <italic>IRAK1</italic> and <italic>IRAK2</italic></title><p>HeLa cells were transfected with two pX459 plasmids which contains gRNA sequence for <italic>IRAK1</italic> and <italic>IRAK2</italic>. As the negative control, empty pX459 plasmid was transfected. Forty-eight hr after the pX459 transfection, puromycin (2 μg/ml) was added to the medium. After 48 hr selection with puromycin, the same number of cells were seeded to new dishes and incubated in fresh media without antibiotics for 48 hr. Knockout efficiency was check by immunoblotting using WCL samples.</p></sec><sec id="s4-8"><title>DSP-crosslinking</title><p>Doxycycline-inducible FLAG-HA-Regnase-1-expressing HeLa cells were treated with doxycycline (1 μg/ml, Sigma) and incubated at 37°C for 4 hr before the DSP-crosslinking. As a negative control, cells were incubated without doxycycline, and for the IL-1β-stimulated sample, cells were stimulated with human IL-1β (10 ng/ml, R and D Systems) 2 hr before the crosslinking. After the incubation, cells were washed twice with pre-warmed PBS, and then incubated in PBS containing 0.1 mM DSP (TCI) at 37°C for 30 min. After crosslinking, cells were washed once with pre-warmed PBS and incubated in STOP solution (PBS containing 1 M Tris-HCl pH 7.4) at room temperature for 15 min. Cells were then washed with ice-cold PBS twice, followed by cell lysis and immunoprecipitation.</p></sec><sec id="s4-9"><title>Immunoprecipitation</title><p>Before immunoprecipitation, pre-washed Dynabeads Protein G (Invitrogen) were incubated with either anti-FLAG antibody (Sigma), anti-HA antibody (Sigma), or anti-Myc antibody (Sigma) at 4°C with rotation for 1 hr.</p><p>For DSP-crosslinked samples, cells were lysed in IP buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, and 0.5% (vol/vol) NP-40) with cOmplete Mini EDTA-free (Sigma), PhosSTOP (Sigma), and 200 U/ml of Benzonase (Millipore) and incubated on ice for 10 min. The lysates were centrifuged at 15,000 rpm for 5 min and the supernatants were incubated with anti-FLAG-antibody-bound Dynabeads at 4°C with rotation for 2 hr. The beads were then washed with IP buffer three times and incubated in FLAG-elution buffer (100 μg/ml FLAG peptides (Sigma), 50 mM Tris-HCl pH7.4, and 150 mM NaCl) at 4°C with rotation for 10 min twice. Eluted proteins were then immunoprecipitated using anti-HA-antibody-bound Dynabeads at 4°C with rotation for 2 hr. After the second immunoprecipitation, the beads were washed three times with IP buffer and the proteins were eluted in Urea elution buffer (8 M Urea and 50 mM Tris-HCl pH 8.0). The samples were stored at -80°C until trypsin digestion. Proteins were reduced with 10 mM dithiothreitol (Fujifilm Wako) for 30 min, alkylated with 50 mM iodoacetamide (Fujifilm Wako) for 30 min in the dark, diluted fourfold with 50 mM ammonium bicarbonate (ABC) buffer, and then trypsin digestion was performed. After overnight incubation, digestion was stopped by adding trifluoroacetic acid (TFA) (Fujifilm Wako) to a final concentration of 0.5%. The peptide mixture solution was desalted with SDB-XC StageTips (<xref ref-type="bibr" rid="bib41">Rappsilber et al., 2007</xref>). The eluates were dried and resuspended in 200 mM 2-[4-2(2-hydroxyethyl)-1-piperazine]ethanesulfonic acid (HEPES) pH 8.5, mixed with 0.1 mg of TMT10-plex labeling reagents (Thermo Fisher Scientific) dissolved in 5 μL acetonitrile (ACN), and incubated for 1 hr at room temperature. The reaction mixtures were quenched by adding hydroxylamine (Sigma) to give a final concentration of 0.33%. After 15 min incubation, the samples were acidified with trifluoroacetic acid, diluted to 5% ACN, and desalted using SDB-XC StageTips. Peptides were dried, resolved in 5 mM ABC buffer and fractionated with a C18-StageTip. Peptides were eluted with 5 mM ABC containing acetonitrile (12.5%, 15%, 17.5%, 20%, 22.5% and 80%) in step gradient manner. Totally six fractions were obtained and analyzed by LC/MS/MS.</p><p>For the identification of phosphorylation sites of Regnase-1, HeLa cells expressing FLAG-HA-Regnase-1 or FLAG-Regnase-1 were stimulated with IL-1β (10 ng/ml) or IL-17A (50 ng/ml) respectively for 4 hr. The cells were washed with ice-cold PBS twice and lysed in IP buffer with cOmplete Mini EDTA-free and PhosSTOP. Regnase-1 was immunoprecipitated using anti FLAG antibody as described above and eluted from Dynabeads in SDS sample buffer (50 mM Tris–HCl pH 6.8, 2% (wt/vol) SDS, 15% (vol/vol) 2-mercaptoethanol, 10% (vol/vol) glycerol and bromophenol blue), followed by incubation at 95°C for 5 min. Regnase-1was isolated by electrophoresis and the pieces of the gel containing Regnase-1 was stored at 4°C until trypsin digestion. The gels were de-stained for 30 min with 200 μL of 50 mM ABC / 50% ACN. Then the gels were dehydrated by the addition of 100% ACN. Proteins were reduced with 500 μL of 10 mM dithiothreitol / 50 mM ABC for 30 min, alkylated with 50 mM iodoacetamide / 50 mM ABC for 30 min in the dark. The gels were washed two times with 200 μL of 0.5% acetic acid / 50% methanol. After washing, gels were re-equilibrated with 50 mM ABC, and subsequently dehydrated by the addition of 100% ACN. 10 μL of trypsin solution (10 ng/μL in 50 mM ABC) was added to gel pieces and incubated for 5 min. Another 50 μL of 50 mM ABC buffer was added to gel samples and incubated at 37°C for overnight. After that, elastase (Promega) (150 ng/μL in water) was added to the final concentration of 7.5 ng/μL and incubated for 30 min at 37°C (<xref ref-type="bibr" rid="bib8">Dau et al., 2020</xref>). Digestion was stopped by the addition of 5 μL of 10% TFA. The supernatants were recovered into fresh Eppendorf tubes, and two additional extraction steps were performed with 50% ACN / 0.1% TFA and 80% ACN / 0.1% TFA. The peptides in the supernatants were dried, resuspended in 0.1% TFA, and desalted using SDB-XC StageTips.</p><p>For detecting protein-protein binding, cells were lysed in IP Buffer with cOmplete Mini EDTA-free and PhosSTOP and immunoprecipitated as described above using indicated antibodies. The proteins were eluted in the mixture of IP Buffer and SDS sample buffer (2:1) and incubated at 95°C for 5 min.</p><p>For detecting protein-RNA binding, cells were lysed in IP Buffer with cOmplete Mini EDTA-free and RNaseOut (Invitrogen) and immunoprecipitated as described above using indicated antibodies. Some of the precipitates were eluted in the mixture of IP Buffer and SDS sample buffer (2:1) to elute proteins and the others were eluted in TRIzol Reagent (Invitrogen) for RNA isolation.</p></sec><sec id="s4-10"><title>LC-MS/MS</title><p>LC/MS/MS analyses were performed with an Orbitrap Fusion Lumos (Thermo Fisher Scientific) connected to an Ultimate 3000 pump (Thermo Fisher Scientific) and an HTC-PAL autosampler (CTC analytics). Peptides were separated by a self-pulled needle column (150 mm length, 100 μm ID, 6 μm needle opening) packed with Reprosil-Pur 120 C18-AQ 3 μm reversed-phase material (Dr. Maisch GmbH), using a 20 min or 65 min gradient of 5–40% B (mobile phase A: 0.5% acetic acid, mobile phase B: 0.5% acetic acid / 80% acetonitrile) at a flow rate of 500 nL/min. The applied ESI voltage was 2.4 kV. For TMT-labeled samples, the following parameters were applied: MS scan range of 375–1500, MS1 orbitrap resolution of 120,000, quadrupole isolation window of 0.7, HCD (higher-energy collision dissociation) collision energy of 38%, MS2 orbitrap resolution of 50,000, AGC target value of 50000. For non-labeled samples, the following parameters were applied: MS scan range of 300–1500, MS1 orbitrap resolution of 120,000, quadrupole isolation window of 1.6, HCD collision energy of 30%, MS2 orbitrap resolution of 15,000, MS2 AGC target value of 50,000.</p></sec><sec id="s4-11"><title>Database searching and data processing</title><p>For DSP-crosslinked samples, peptides were identified with Mascot version 2.6.1 (Matrix Science) against the sequence of Mouse Regnase-1 in addition to the human database from UniprotKB/Swiss-Prot release 2017/04 and with a precursor ion mass tolerance of 5 ppm and a product ion mass tolerance of 20 ppm. Carbamidomethyl (C), TMT6plex (K) and TMT6plex (N-term) were set as a fixed modification, oxidation (M) was allowed as a variable modification, and up to two missed cleavages are allowed with strict Trypsin/P specificity. Identified peptides were rejected if the Mascot score was below the 95% confidence limit based on the identity score of each peptide. The quantification of peptides was based on the TMT reporter ion intensities in MS2 spectra. Protein quantitative values were calculated by summing the corresponding peptide intensity values. Only proteins with at least two unique peptides were used for further analysis.</p><p>For the identification of phosphorylation sites of Regnase-1, peptides were identified with Mascot version 2.7.0 against the sequence of mouse Regnase-1 with a precursor ion mass tolerance of 5 ppm and a product ion mass tolerance of 20 ppm. Carbamidomethyl (C) was set as a fixed modification, oxidation (M) and phosphorylation (STY) were allowed as variable modifications, and up to two missed cleavages are allowed with semitrypsin specificity. Identified peptides were rejected if the Mascot score was below the 99% confidence limit based on the identity score of each peptide. The label-free quantification of peptides was based on the peak area in the extracted ion chromatograms using Skyline-daily software version 21.0.9.118 (<xref ref-type="bibr" rid="bib25">MacLean et al., 2010</xref>). The peak area ratios between stimulated and non-stimulated samples were calculated, log-scaled, and normalized by the median. For quantitation of phosphosites, the peak area ratios of all monophosphopeptides containing the phosphosites of interest were averaged. Phosphosite localization was evaluated with a site-determining ion combination method based on the presence of site-determining y- or b-ions in the peak lists of the fragment ions, which supported the phosphosites unambiguously (<xref ref-type="bibr" rid="bib34">Nakagami et al., 2010</xref>).</p><p>Protein-protein interaction network of the Regnase-1-associating proteins (Log<sub>2</sub> fold change over negative control &gt; 2) was analyzed using STRING database (<xref ref-type="bibr" rid="bib45">Szklarczyk et al., 2019</xref>) and visualized in Cytoscape (<xref ref-type="bibr" rid="bib43">Shannon et al., 2003</xref>). Keratins contaminated in the samples were omitted from the analysis.</p></sec><sec id="s4-12"><title>λ-protein phosphatase (λPP) treatment</title><p>HeLa cells transiently expressing HA-14-3-3ε were stimulated with or without IL-1β (10 ng/ml) for 4 hr and lysed in IP Buffer. Some of the lysates were used in immunoprecipitation as described above. The proteins were eluted using 250 μg/ml of HA peptides as described above. The lysate and the precipitates were treated with Lambda Protein Phosphatase (NEB) according to manufacturer's instructions. For the λPP-negative samples, the same amount of IP Buffer was added instead of λPP.</p></sec><sec id="s4-13"><title>Immunoblotting</title><p>Cells were lysed in IP Buffer or RIPA buffer (1% (vol/vol) NP-40, 0.1% (wt/vol) SDS, 1% (wt/vol) sodium deoxycholate, 150 mM NaCl, 20 mM Tris-HCl pH 8.0, and 10 mM EDTA) with cOmplete Mini EDTA-free and PhosSTOP. The lysates were incubated on ice for 5 min and centrifuged at 15,000 rpm for 5 min. The supernatants were mixed with SDS sample buffer (2:1) and incubated at 95°C for 5 min. SDS-PAGE was performed using e-PAGEL 7.5% or 5~20% (ATTO) and the proteins were transferred onto 0.2 μm pore size Immun-Blot PVDF membranes (Bio-Rad), followed by blocking with 5% skim milk. The antibodies used in immunoblotting were listed in the key resources table. Luminescence was detected with Amersham Imager 600 (cytiva) and the images were analyzed with Fiji (<xref ref-type="bibr" rid="bib42">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-14"><title>RNA isolation and RT-qPCR</title><p>Cells were lysed in TRIzol Reagent, and the RNA was isolated according to manufacturer's instructions. For the isolation of the RNA precipitated with Regnase-1, RNA was isolated using RNA Clean and Concentrator-5 (Zymo Research). RNA was reverse transcribed by using ReverTra Ace (TOYOBO). cDNA was amplified by using PowerUp SYBR Green Master Mix (Applied Biosystems) and measured with StepOnePlus Real-Time PCR System (Applied Biosystems). To analyze mRNA expression, each RNA level was normalized with 18S or ACTB. The primers used in qPCR were listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-15"><title>RNA sequencing</title><p>PECs were harvested from <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> mice as described above. PECs were stimulated with LPS (100 ng/ml) for indicated time and the RNA was collected and isolated using TRIzol Reagent. cDNA library was prepared using NEBNext Ultra RNA Library Prep Kit for Illumina (NEB) and sequenced on NextSeq 500 System (Illumina) according to the manufacturer’s instructions. Acquired data was analyzed using Galaxy (<xref ref-type="bibr" rid="bib1">Afgan et al., 2018</xref>). Briefly, identified reads were mapped on the murine genome (mm10) using HISAT2 (paired end, unstranded) (Galaxy Version 2.1.0), and the mapped reads were counted using featureCounts (Galaxy Version 1.6.3).</p></sec><sec id="s4-16"><title>ELISA</title><p>Cytokine concentration was measured by using IL-6 Mouse Uncoated ELISA Kit (Invitrogen) according to manufacturer's instructions. Luminescence was detected with iMark Microplate Reader (Bio-Rad).</p></sec><sec id="s4-17"><title>Luciferase assay</title><p>5xNF-κB firefly luciferase reporter vector, Renilla luciferase vector, and IRAK1-expressing vector were transfected in HeLa cells and the luciferase activity was measured by using PicaGene Dual Sea Pansy Luminescence Kit (TOYO B-Net). NF-κB activation was calculated by normalizing Firefly luciferase activity with Renilla luciferase activity.</p></sec><sec id="s4-18"><title>Mathematical model</title><p>We developed two dynamical models for the inflammation system regulated by Regnase-1 based on different assumptions of the functions of 14-3-3-bound Regnase-1.</p></sec><sec id="s4-19"><title>Model 1</title><p>In the first model, we assumed that the 14-3-3-bound Regnase-1 does not have the function of degrading its target mRNAs (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). The ordinary differential equations are given as follows:<disp-formula id="equ1"><label>(1.1)</label><mml:math id="m1"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ2"><mml:math id="m2"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ3"><mml:math id="m3"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ4"><mml:math id="m4"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula>where <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf2"><mml:mi mathvariant="normal"/><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf3"><mml:mi mathvariant="normal"/><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the abundance of <italic>Il6</italic> mRNA, <italic>Zc3h12a</italic> mRNA, Reg1 Protein, and 14-3-3-bound Reg1 Protein, respectively; <inline-formula><mml:math id="inf5"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the transcription rate constant of <italic>Il6</italic>, and <italic>Zc3h12a</italic>, respectively; <inline-formula><mml:math id="inf7"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the translation rate constant of <italic>Zc3h12a</italic>; <inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the Reg1-induced degradation rate constant of <italic>Il6</italic> mRNA and <italic>Zc3h12a</italic> mRNA, respectively; <inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the Reg1-independent degradation rate constant of Reg1 protein, <italic>Il6</italic> mRNA, and <italic>Zc3h12a</italic> mRNA, respectively; <inline-formula><mml:math id="inf13"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the ubiquitin-dependent degradation rate constant of Reg1 protein; <inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the binding rate constant of Reg1 protein to 14-3-3; <inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the natural degradation rate constant of 14-3-3-bound Reg1 protein; <inline-formula><mml:math id="inf16"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the dissociation rate constant of Reg1 from 14-3-3. <inline-formula><mml:math id="inf17"><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> is the strength of TLR stimulation, which is given as the following form (<xref ref-type="bibr" rid="bib31">Mino et al., 2019</xref>):<disp-formula id="equ5"><label>(1.2)</label><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="center center" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s4-20"><title>Model 2</title><p>We also developed an alternative model in which the 14-3-3-bound Regnase-1 maintains functions of degrading its target mRNAs (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). The ordinary differential equations are given as follows:<disp-formula id="equ6"><label>(1.3)</label><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ7"><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ8"><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ9"><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the abundance of <italic>Il6</italic> mRNA, <italic>Zc3h12a</italic> mRNA, Reg1 Protein, 14-3-3-bound Reg1 Protein, respectively; <inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the 14-3-3-bound Reg1-induced degradation rate constant of <italic>Il6</italic> mRNA and <italic>Zc3h12a</italic> mRNA, respectively. The other parameters are defined in the same way as Model 1.</p><p>To determine which model is consistent with the experimental observations, we focus on the experimental findings that there was no difference in the abundance of <italic>Il</italic>6 mRNA, <italic>Zc3h12a</italic> mRNA, and Reg1- protein (without 14-3-3 bound) between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells in the late phase of stimulation (<xref ref-type="fig" rid="fig4">Figure 4A,B,D and E</xref>). We will show that in Model 2 (<xref ref-type="disp-formula" rid="equ6">Equation 1.3</xref>), the abundance of the <italic>Il6</italic> mRNAs should be different between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells under the condition that amount of the 14-3-3-free Reg1 protein is comparable between them.</p></sec><sec id="s4-21"><title>Analysis of the equilibrium</title><sec id="s4-21-1"><title>Lemma 1</title><p>For <italic>Zc3h12a</italic><sup>WT/WT</sup> cells, there exists only one nonnegative (biologically meaningful) equilibrium of the system (<xref ref-type="disp-formula" rid="equ6">Equation 1.3</xref>) if and only if <inline-formula><mml:math id="inf24"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>. If <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, there is no equilibrium. For <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells, there always exists only one nonnegative (biologically meaningful) equilibrium.</p></sec><sec id="s4-21-2"><title>Proof of lemma 1</title><p>Setting all the derivatives of <xref ref-type="disp-formula" rid="equ6">Equation (1.3)</xref> equal to zero yields<disp-formula id="equ10"><label>(1.4)</label><mml:math id="m10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ11"><mml:math id="m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ12"><mml:math id="m12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ13"><mml:math id="m13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> are fixed points of <inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, respectively. Given that <inline-formula><mml:math id="inf34"><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>→</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mi/></mml:math></inline-formula> as <inline-formula><mml:math id="inf35"><mml:mi>t</mml:mi><mml:mo>→</mml:mo><mml:mi>∞</mml:mi></mml:math></inline-formula>, we assume <inline-formula><mml:math id="inf36"><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>≈</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> at the equilibrium.</p><p>It follows from <xref ref-type="disp-formula" rid="equ10">Equation (1.4)</xref> that<disp-formula id="equ14"><label>(1.5a)</label><mml:math id="m14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>K</mml:mi><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mi>K</mml:mi><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ15"><label>(1.5b)</label><mml:math id="m15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ16"><label>(1.5c)</label><mml:math id="m16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi>K</mml:mi><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ17"><label>(1.5d)</label><mml:math id="m17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>where<disp-formula id="equ18"><mml:math id="m18"><mml:mi>K</mml:mi><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>It is easy to see that the quadratic <xref ref-type="disp-formula" rid="equ14">Equation (1.5a)</xref> has a nonnegative solution if <inline-formula><mml:math id="inf37"><mml:mi>K</mml:mi><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, that is, <inline-formula><mml:math id="inf38"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>. If <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>K</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, <xref ref-type="disp-formula" rid="equ14">Equation (1.5a)</xref> has no nonnegative solution. If <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, it follows from (<xref ref-type="disp-formula" rid="equ15">Equation 1.5b</xref>), (<xref ref-type="disp-formula" rid="equ16">Equation 1.5c</xref>), and (<xref ref-type="disp-formula" rid="equ17">Equation 1.5d</xref>) that <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>For <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells, we assume that <inline-formula><mml:math id="inf44"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>. Substituting this equation into <xref ref-type="disp-formula" rid="equ10">Equation (1.4)</xref> yields<disp-formula id="equ19"><label>(1.6)</label><mml:math id="m19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ20"><mml:math id="m20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ21"><mml:math id="m21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ22"><mml:math id="m22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> are fixed points of <inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells, respectively.</p><p>It follows from (1.6) that<disp-formula id="equ23"><label>(1.7a)</label><mml:math id="m23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ24"><label>(1.7b)</label><mml:math id="m24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ25"><label>(1.7c)</label><mml:math id="m25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>It is easy to see that the quadratic <xref ref-type="disp-formula" rid="equ23">Equation (1.7a)</xref> has a nonnegative solution. If <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, it follows from (<xref ref-type="disp-formula" rid="equ24">Equation 1.7b</xref>) and (<xref ref-type="disp-formula" rid="equ25">Equation 1.7c</xref>) that <inline-formula><mml:math id="inf54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> <inline-formula><mml:math id="inf55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>Lemma 2. There exists only one nonnegative (biologically meaningful) equilibrium of the system (<xref ref-type="disp-formula" rid="equ1">Equation 1.1</xref>) if and only if <inline-formula><mml:math id="inf56"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>. If <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, there is no equilibrium. For <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells, there always exists only one nonnegative (biologically meaningful) equilibrium.</p><p>Proof of lemma2:</p><p>With <inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> in lemma 1, we get the same conclusion.</p></sec></sec><sec id="s4-22"><title>Consistency with the experiments</title><p>The experimental observation shows that there was no difference in the abundance of Reg1 protein between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells at the late phase of stimulation (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>), which implies<disp-formula id="equ26"><label>(1.8)</label><mml:math id="m26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>≈</mml:mo><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula>based on the alternative model (1.3).</p><p>From (<xref ref-type="disp-formula" rid="equ10">Equation 1.4</xref>) and (<xref ref-type="disp-formula" rid="equ19">Equation 1.6</xref>), we get<disp-formula id="equ27"><label>(1.9a)</label><mml:math id="m27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ28"><mml:math id="m28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ29"><label>(1.9b)</label><mml:math id="m29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ30"><mml:math id="m30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>By (<xref ref-type="disp-formula" rid="equ26">Equation 1.8</xref>), (<xref ref-type="disp-formula" rid="equ27">Equation 1.9a</xref>), and (<xref ref-type="disp-formula" rid="equ29">Equation 1.9b</xref>), we obtain<disp-formula id="equ31"><label>(1.10a)</label><mml:math id="m31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ32"><label>(1.10b)</label><mml:math id="m32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p><xref ref-type="disp-formula" rid="equ31">Equation 1.10a</xref> and <xref ref-type="disp-formula" rid="equ32">Equation 1.10b</xref> implies that in Model 2, the abundance of <italic>Il6</italic> and <italic>Zc3h12a</italic> mRNA in <italic>Zc3h12a</italic><sup>WT/WT</sup> cells should be smaller than that in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells at the late phase under the condition that amount of the Reg1 protein is comparable (<xref ref-type="disp-formula" rid="equ26">Equation 1.8</xref>) between these two cells. It contradicts experimental observation that the abundance of the <italic>Il6</italic> and <italic>Zc3h12a</italic> mRNAs did not differ between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells (<xref ref-type="fig" rid="fig4">Figure 4D–I</xref>). Thus, Model 2 (<xref ref-type="disp-formula" rid="equ6">Equation 1.3</xref>) is not consistent with the experimental findings.</p><p>In contrast, in Model 1 (<xref ref-type="disp-formula" rid="equ1">Equation 1.1</xref>), we assume from experimental findings that<disp-formula id="equ33"><label>(1.11)</label><mml:math id="m33"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>≈</mml:mo><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:math></disp-formula>just like (<xref ref-type="disp-formula" rid="equ26">Equation 1.8</xref>), where <inline-formula><mml:math id="inf59"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is the fixed point of <inline-formula><mml:math id="inf60"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> in <italic>Zc3h12a</italic><sup>WT/WT</sup> cells and <inline-formula><mml:math id="inf61"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is the fixed point of <inline-formula><mml:math id="inf62"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells based on the model (<xref ref-type="disp-formula" rid="equ1">Equation 1.1</xref>).</p><p>By substituting <inline-formula><mml:math id="inf63"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> into (<xref ref-type="disp-formula" rid="equ27">Equation 1.9a</xref>) and (<xref ref-type="disp-formula" rid="equ29">Equation 1.9b</xref>), we obtain<disp-formula id="equ34"><label>(1.12a)</label><mml:math id="m34"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ35"><mml:math id="m35"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ36"><label>(1.12b)</label><mml:math id="m36"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ37"><mml:math id="m37"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>where <inline-formula><mml:math id="inf64"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf65"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> are fixed points of <inline-formula><mml:math id="inf66"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf67"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, respectively in <italic>Zc3h12a</italic><sup>WT/WT</sup> cells and <inline-formula><mml:math id="inf68"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf69"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> are fixed points of <inline-formula><mml:math id="inf70"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf71"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, respectively in <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells.</p><p>By (<xref ref-type="disp-formula" rid="equ33">Equation 1.11</xref>), (<xref ref-type="disp-formula" rid="equ34">Equation 1.12a</xref>), and (<xref ref-type="disp-formula" rid="equ36">Equation 1.12b</xref>), we obtain<disp-formula id="equ38"><label>(1.13a)</label><mml:math id="m38"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>≈</mml:mo><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:math></disp-formula><disp-formula id="equ39"><label>(1.13b)</label><mml:math id="m39"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>≈</mml:mo><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:math></disp-formula></p><p>In this case, (<xref ref-type="disp-formula" rid="equ38">Equation 1.13a</xref>) and (<xref ref-type="disp-formula" rid="equ39">Equation 1.13b</xref>) are in agreement with the experimental facts that that the abundance of the target mRNAs did not differ between <italic>Zc3h12a</italic><sup>WT/WT</sup> and <italic>Zc3h12a</italic><sup>S513A/S513A</sup> cells.</p><p>These mathematical analyses indicate that Model 1 (<xref ref-type="disp-formula" rid="equ1">Equation 1.1</xref>), but not Model 2 (<xref ref-type="disp-formula" rid="equ6">Equation 1.3</xref>), is consistent with the experimental findings.</p></sec><sec id="s4-23"><title>Immunofluorescence</title><p>Cells were cultured on cover glass, fixed with 4%-Paraformaldehyde Phosphate Buffer Solution (nacalai tesque), and permeabilized with 0.5% (vol/vol) Triton X-100 (nacalai tesque) in PBS, followed by incubation in blocking solution (2% (vol/vol) goat serum (FUJIFILM Wako Pure Chemical) and 0.1% (wt/vol) gelatin in PBS). The antibodies used in Immunofluorescence were listed in the key resources table. DNA was stained with Hoechst 33342 (Invitrogen). Fluorescence was detected with TCS SPE (Leica). Acquired images were analyzed with Fiji (<xref ref-type="bibr" rid="bib42">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-24"><title>Amino acid sequence analysis</title><p>Amino acid sequence of each protein was obtained from NCBI. The results of T-coffee alignment (<xref ref-type="bibr" rid="bib37">Notredame et al., 2000</xref>) were visualized by using Jalview (<xref ref-type="bibr" rid="bib53">Waterhouse et al., 2009</xref>). Secondary structure was predicted by using PSIPRED 4.0 (<xref ref-type="bibr" rid="bib5">Buchan and Jones, 2019</xref>; <xref ref-type="bibr" rid="bib20">Jones, 1999</xref>). NES prediction was performed by using LocNES (<xref ref-type="bibr" rid="bib56">Xu et al., 2015</xref>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank S Ogawa and N Kakiuchi in Kyoto university for performing RNA sequencing and providing <italic>ZC3H12A</italic>-KO HeLa cells, Y Okumoto for secretarial assistance and lab members for helpful discussion. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI [18H05278]; AMED-FORCE [JP20gm4010002] from Japan Agency for Medical Research and Development and the JSPS through Core-to-Core Program. KA was supported by ‘Kibou Projects’ Scholarship for doctoral Students in Immunology. TM was funded by JSPS KAKENHI (19H03488), Grant-in-Aid for Scientific Research on Innovative Areas ‘Genome Science’ (221S0002 and 16H06279), Takeda Science Foundation, the Uehara Memorial Foundation, Shimizu Foundation for Immunology and Neuroscience, Naito Foundation, Senri Life Science Foundation, Nakajima Foundation, and Mochida Memorial Foundation for Medical and Pharmaceutical Research.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All animal experiments were conducted in compliance with the guidelines of the Kyoto University animal experimentation committee. (Approval number: MedKyo21057).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw data of the results of immunoblotting are zipped in Source Data Files.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71966-data1-v3.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primer sequences used in qPCR.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71966-supp1-v3.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-71966-transrepform-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Mass spectrometry data (PXD026561) is available at <ext-link ext-link-type="uri" xlink:href="https://repository.jpostdb.org/entry/JPST001201">https://repository.jpostdb.org/entry/JPST001201</ext-link>.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Phosphorylation-dependent Regnase-1 interactome</data-title><source>JPOST</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://repository.jpostdb.org/entry/JPST001201">PXD026561</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Akaki</surname><given-names>K</given-names></name><name><surname>Hia</surname><given-names>F</given-names></name><name><surname>Kakiuchi</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Transcriptome analysis of LPS stimulated PECs (WT and Zc3h12a S513A)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE180028">GSE180028</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afgan</surname> <given-names>E</given-names></name><name><surname>Baker</surname> <given-names>D</given-names></name><name><surname>Batut</surname> <given-names>B</given-names></name><name><surname>van den Beek</surname> <given-names>M</given-names></name><name><surname>Bouvier</surname> <given-names>D</given-names></name><name><surname>Cech</surname> <given-names>M</given-names></name><name><surname>Chilton</surname> <given-names>J</given-names></name><name><surname>Clements</surname> <given-names>D</given-names></name><name><surname>Coraor</surname> <given-names>N</given-names></name><name><surname>Grüning</surname> <given-names>BA</given-names></name><name><surname>Guerler</surname> <given-names>A</given-names></name><name><surname>Hillman-Jackson</surname> <given-names>J</given-names></name><name><surname>Hiltemann</surname> <given-names>S</given-names></name><name><surname>Jalili</surname> <given-names>V</given-names></name><name><surname>Rasche</surname> <given-names>H</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name><name><surname>Goecks</surname> <given-names>J</given-names></name><name><surname>Taylor</surname> <given-names>J</given-names></name><name><surname>Nekrutenko</surname> <given-names>A</given-names></name><name><surname>Blankenberg</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W537</fpage><lpage>W544</lpage><pub-id pub-id-type="doi">10.1093/nar/gky379</pub-id><pub-id pub-id-type="pmid">29790989</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aitken</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>14-3-3 proteins: a historic overview</article-title><source>Seminars in Cancer Biology</source><volume>16</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2006.03.005</pub-id><pub-id pub-id-type="pmid">16678438</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Uematsu</surname> <given-names>S</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pathogen recognition and innate immunity</article-title><source>Cell</source><volume>124</volume><fpage>783</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.015</pub-id><pub-id pub-id-type="pmid">16497588</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Post-transcriptional regulons coordinate the initiation and resolution of inflammation</article-title><source>Nature Reviews Immunology</source><volume>10</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nri2685</pub-id><pub-id pub-id-type="pmid">20029446</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname> <given-names>DWA</given-names></name><name><surname>Jones</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The PSIPRED Protein Analysis Workbench: 20 years on</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W402</fpage><lpage>W407</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz297</pub-id><pub-id pub-id-type="pmid">31251384</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname> <given-names>S</given-names></name><name><surname>Ricci</surname> <given-names>EP</given-names></name><name><surname>Mercier</surname> <given-names>BC</given-names></name><name><surname>Moore</surname> <given-names>MJ</given-names></name><name><surname>Fitzgerald</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Post-transcriptional regulation of gene expression in innate immunity</article-title><source>Nature Reviews Immunology</source><volume>14</volume><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/nri3682</pub-id><pub-id pub-id-type="pmid">24854588</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Cox</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Barretto</surname> <given-names>R</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dau</surname> <given-names>T</given-names></name><name><surname>Bartolomucci</surname> <given-names>G</given-names></name><name><surname>Rappsilber</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteomics Using Protease Alternatives to Trypsin Benefits from Sequential Digestion with Trypsin</article-title><source>Analytical Chemistry</source><volume>92</volume><fpage>9523</fpage><lpage>9527</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.0c00478</pub-id><pub-id pub-id-type="pmid">32628831</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname> <given-names>M</given-names></name><name><surname>Hatzubai</surname> <given-names>A</given-names></name><name><surname>Andersen</surname> <given-names>JS</given-names></name><name><surname>Ben-Shushan</surname> <given-names>E</given-names></name><name><surname>Fisher</surname> <given-names>GZ</given-names></name><name><surname>Yaron</surname> <given-names>A</given-names></name><name><surname>Bauskin</surname> <given-names>A</given-names></name><name><surname>Mercurio</surname> <given-names>F</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name><name><surname>Ben-Neriah</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Pseudosubstrate regulation of the SCF(beta-TrCP) ubiquitin ligase by hnRNP-U</article-title><source>Genes &amp; Development</source><volume>16</volume><fpage>439</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1101/gad.218702</pub-id><pub-id pub-id-type="pmid">11850407</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname> <given-names>KA</given-names></name><name><surname>Kagan</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Toll-like Receptors and the Control of Immunity</article-title><source>Cell</source><volume>180</volume><fpage>1044</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.041</pub-id><pub-id pub-id-type="pmid">32164908</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flannery</surname> <given-names>SM</given-names></name><name><surname>Keating</surname> <given-names>SE</given-names></name><name><surname>Szymak</surname> <given-names>J</given-names></name><name><surname>Bowie</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human Interleukin-1 Receptor-associated Kinase-2 Is Essential for Toll-like Receptor-mediated Transcriptional and Post-transcriptional Regulation of Tumor Necrosis Factor α</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>23688</fpage><lpage>23697</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.248351</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname> <given-names>H</given-names></name><name><surname>Coburn</surname> <given-names>J</given-names></name><name><surname>Collier</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The eukaryotic host factor that activates exoenzyme S of <italic>Pseudomonas aeruginosa</italic> is a member of the 14-3-3 protein family</article-title><source>PNAS</source><volume>90</volume><fpage>2320</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.6.2320</pub-id><pub-id pub-id-type="pmid">8460141</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujihara</surname> <given-names>Y</given-names></name><name><surname>Ikawa</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR/Cas9-based genome editing in mice by single plasmid injection</article-title><source>Methods in Enzymology</source><volume>546</volume><fpage>319</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-801185-0.00015-5</pub-id><pub-id pub-id-type="pmid">25398347</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottipati</surname> <given-names>S</given-names></name><name><surname>Rao</surname> <given-names>NL</given-names></name><name><surname>Fung-Leung</surname> <given-names>WP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IRAK1: a critical signaling mediator of innate immunity</article-title><source>Cellular Signalling</source><volume>20</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2007.08.009</pub-id><pub-id pub-id-type="pmid">17890055</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>CJ</given-names></name><name><surname>Ma</surname> <given-names>XK</given-names></name><name><surname>Xing</surname> <given-names>YH</given-names></name><name><surname>Zheng</surname> <given-names>CC</given-names></name><name><surname>Xu</surname> <given-names>YF</given-names></name><name><surname>Shan</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Carmichael</surname> <given-names>GG</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>LL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct Processing of lncRNAs Contributes to Non-conserved Functions in Stem Cells</article-title><source>Cell</source><volume>181</volume><fpage>621</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.006</pub-id><pub-id pub-id-type="pmid">32259487</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>S</given-names></name><name><surname>Baltimore</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules</article-title><source>Nature Immunology</source><volume>10</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/ni.1699</pub-id><pub-id pub-id-type="pmid">19198593</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartupee</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Hamilton</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Interleukin 1α-induced NFκB Activation and Chemokine mRNA Stabilization Diverge at IRAK1</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>15689</fpage><lpage>15693</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801346200</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutten</surname> <given-names>S</given-names></name><name><surname>Kehlenbach</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CRM1-mediated nuclear export: to the pore and beyond</article-title><source>Trends in Cell Biology</source><volume>17</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2007.02.003</pub-id><pub-id pub-id-type="pmid">17317185</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname> <given-names>H</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name><name><surname>Teraguchi</surname> <given-names>S</given-names></name><name><surname>Matsushita</surname> <given-names>K</given-names></name><name><surname>Uehata</surname> <given-names>T</given-names></name><name><surname>Kuniyoshi</surname> <given-names>K</given-names></name><name><surname>Satoh</surname> <given-names>T</given-names></name><name><surname>Saitoh</surname> <given-names>T</given-names></name><name><surname>Matsushita</surname> <given-names>M</given-names></name><name><surname>Standley</surname> <given-names>DM</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1</article-title><source>Nature Immunology</source><volume>12</volume><fpage>1167</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1038/ni.2137</pub-id><pub-id pub-id-type="pmid">22037600</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Protein secondary structure prediction based on position-specific scoring matrices</article-title><source>Journal of Molecular Biology</source><volume>292</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1999.3091</pub-id><pub-id pub-id-type="pmid">10493868</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakiuchi</surname> <given-names>N</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Uchino</surname> <given-names>M</given-names></name><name><surname>Kihara</surname> <given-names>T</given-names></name><name><surname>Akaki</surname> <given-names>K</given-names></name><name><surname>Inoue</surname> <given-names>Y</given-names></name><name><surname>Kawada</surname> <given-names>K</given-names></name><name><surname>Nagayama</surname> <given-names>S</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Yamamoto</surname> <given-names>S</given-names></name><name><surname>Matsuura</surname> <given-names>M</given-names></name><name><surname>Horimatsu</surname> <given-names>T</given-names></name><name><surname>Hirano</surname> <given-names>T</given-names></name><name><surname>Goto</surname> <given-names>N</given-names></name><name><surname>Takeuchi</surname> <given-names>Y</given-names></name><name><surname>Ochi</surname> <given-names>Y</given-names></name><name><surname>Shiozawa</surname> <given-names>Y</given-names></name><name><surname>Kogure</surname> <given-names>Y</given-names></name><name><surname>Watatani</surname> <given-names>Y</given-names></name><name><surname>Fujii</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>SK</given-names></name><name><surname>Kon</surname> <given-names>A</given-names></name><name><surname>Kataoka</surname> <given-names>K</given-names></name><name><surname>Yoshizato</surname> <given-names>T</given-names></name><name><surname>Nakagawa</surname> <given-names>MM</given-names></name><name><surname>Yoda</surname> <given-names>A</given-names></name><name><surname>Nanya</surname> <given-names>Y</given-names></name><name><surname>Makishima</surname> <given-names>H</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Sanada</surname> <given-names>M</given-names></name><name><surname>Sugihara</surname> <given-names>E</given-names></name><name><surname>Sato</surname> <given-names>TA</given-names></name><name><surname>Maruyama</surname> <given-names>T</given-names></name><name><surname>Miyoshi</surname> <given-names>H</given-names></name><name><surname>Taketo</surname> <given-names>MM</given-names></name><name><surname>Oishi</surname> <given-names>J</given-names></name><name><surname>Inagaki</surname> <given-names>R</given-names></name><name><surname>Ueda</surname> <given-names>Y</given-names></name><name><surname>Okamoto</surname> <given-names>S</given-names></name><name><surname>Okajima</surname> <given-names>H</given-names></name><name><surname>Sakai</surname> <given-names>Y</given-names></name><name><surname>Sakurai</surname> <given-names>T</given-names></name><name><surname>Haga</surname> <given-names>H</given-names></name><name><surname>Hirota</surname> <given-names>S</given-names></name><name><surname>Ikeuchi</surname> <given-names>H</given-names></name><name><surname>Nakase</surname> <given-names>H</given-names></name><name><surname>Marusawa</surname> <given-names>H</given-names></name><name><surname>Chiba</surname> <given-names>T</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Seno</surname> <given-names>H</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis</article-title><source>Nature</source><volume>577</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1856-1</pub-id><pub-id pub-id-type="pmid">31853061</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlberg</surname> <given-names>T</given-names></name><name><surname>Hornyak</surname> <given-names>P</given-names></name><name><surname>Pinto</surname> <given-names>AF</given-names></name><name><surname>Milanova</surname> <given-names>S</given-names></name><name><surname>Ebrahimi</surname> <given-names>M</given-names></name><name><surname>Lindberg</surname> <given-names>M</given-names></name><name><surname>Püllen</surname> <given-names>N</given-names></name><name><surname>Nordström</surname> <given-names>A</given-names></name><name><surname>Löverli</surname> <given-names>E</given-names></name><name><surname>Caraballo</surname> <given-names>R</given-names></name><name><surname>Wong</surname> <given-names>EV</given-names></name><name><surname>Näreoja</surname> <given-names>K</given-names></name><name><surname>Thorsell</surname> <given-names>AG</given-names></name><name><surname>Elofsson</surname> <given-names>M</given-names></name><name><surname>De La Cruz</surname> <given-names>EM</given-names></name><name><surname>Björkegren</surname> <given-names>C</given-names></name><name><surname>Schüler</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>14-3-3 proteins activate Pseudomonas exotoxins-S and -T by chaperoning a hydrophobic surface</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3785</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06194-1</pub-id><pub-id pub-id-type="pmid">30224724</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollewe</surname> <given-names>C</given-names></name><name><surname>Mackensen</surname> <given-names>AC</given-names></name><name><surname>Neumann</surname> <given-names>D</given-names></name><name><surname>Knop</surname> <given-names>J</given-names></name><name><surname>Cao</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Wesche</surname> <given-names>H</given-names></name><name><surname>Martin</surname> <given-names>MU</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>5227</fpage><lpage>5236</lpage><pub-id pub-id-type="doi">10.1074/jbc.M309251200</pub-id><pub-id pub-id-type="pmid">14625308</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>la Cour</surname> <given-names>T</given-names></name><name><surname>Gupta</surname> <given-names>R</given-names></name><name><surname>Rapacki</surname> <given-names>K</given-names></name><name><surname>Skriver</surname> <given-names>K</given-names></name><name><surname>Poulsen</surname> <given-names>FM</given-names></name><name><surname>Brunak</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>NESbase version 1.0: a database of nuclear export signals</article-title><source>Nucleic Acids Research</source><volume>31</volume><fpage>393</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1093/nar/gkg101</pub-id><pub-id pub-id-type="pmid">12520031</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname> <given-names>B</given-names></name><name><surname>Tomazela</surname> <given-names>DM</given-names></name><name><surname>Shulman</surname> <given-names>N</given-names></name><name><surname>Chambers</surname> <given-names>M</given-names></name><name><surname>Finney</surname> <given-names>GL</given-names></name><name><surname>Frewen</surname> <given-names>B</given-names></name><name><surname>Kern</surname> <given-names>R</given-names></name><name><surname>Tabb</surname> <given-names>DL</given-names></name><name><surname>Liebler</surname> <given-names>DC</given-names></name><name><surname>MacCoss</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Skyline: an open source document editor for creating and analyzing targeted proteomics experiments</article-title><source>Bioinformatics</source><volume>26</volume><fpage>966</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq054</pub-id><pub-id pub-id-type="pmid">20147306</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maquat</surname> <given-names>LE</given-names></name><name><surname>Tarn</surname> <given-names>WY</given-names></name><name><surname>Isken</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The pioneer round of translation: features and functions</article-title><source>Cell</source><volume>142</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.07.022</pub-id><pub-id pub-id-type="pmid">20691898</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname> <given-names>SC</given-names></name><name><surname>Pederson</surname> <given-names>KJ</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Barbieri</surname> <given-names>JT</given-names></name><name><surname>Fu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Interaction of 14-3-3 with a nonphosphorylated protein ligand, exoenzyme S of <italic>Pseudomonas aeruginosa</italic></article-title><source>Biochemistry</source><volume>38</volume><fpage>5216</fpage><lpage>5221</lpage><pub-id pub-id-type="doi">10.1021/bi982492m</pub-id><pub-id pub-id-type="pmid">10213629</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname> <given-names>K</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name><name><surname>Standley</surname> <given-names>DM</given-names></name><name><surname>Kumagai</surname> <given-names>Y</given-names></name><name><surname>Kawagoe</surname> <given-names>T</given-names></name><name><surname>Miyake</surname> <given-names>T</given-names></name><name><surname>Satoh</surname> <given-names>T</given-names></name><name><surname>Kato</surname> <given-names>H</given-names></name><name><surname>Tsujimura</surname> <given-names>T</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay</article-title><source>Nature</source><volume>458</volume><fpage>1185</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1038/nature07924</pub-id><pub-id pub-id-type="pmid">19322177</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meerbrey</surname> <given-names>KL</given-names></name><name><surname>Hu</surname> <given-names>G</given-names></name><name><surname>Kessler</surname> <given-names>JD</given-names></name><name><surname>Roarty</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>MZ</given-names></name><name><surname>Fang</surname> <given-names>JE</given-names></name><name><surname>Herschkowitz</surname> <given-names>JI</given-names></name><name><surname>Burrows</surname> <given-names>AE</given-names></name><name><surname>Ciccia</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>T</given-names></name><name><surname>Schmitt</surname> <given-names>EM</given-names></name><name><surname>Bernardi</surname> <given-names>RJ</given-names></name><name><surname>Fu</surname> <given-names>X</given-names></name><name><surname>Bland</surname> <given-names>CS</given-names></name><name><surname>Cooper</surname> <given-names>TA</given-names></name><name><surname>Schiff</surname> <given-names>R</given-names></name><name><surname>Rosen</surname> <given-names>JM</given-names></name><name><surname>Westbrook</surname> <given-names>TF</given-names></name><name><surname>Elledge</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo</article-title><source>PNAS</source><volume>108</volume><fpage>3665</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019736108</pub-id><pub-id pub-id-type="pmid">21307310</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mino</surname> <given-names>T</given-names></name><name><surname>Murakawa</surname> <given-names>Y</given-names></name><name><surname>Fukao</surname> <given-names>A</given-names></name><name><surname>Vandenbon</surname> <given-names>A</given-names></name><name><surname>Wessels</surname> <given-names>HH</given-names></name><name><surname>Ori</surname> <given-names>D</given-names></name><name><surname>Uehata</surname> <given-names>T</given-names></name><name><surname>Tartey</surname> <given-names>S</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Suzuki</surname> <given-names>Y</given-names></name><name><surname>Vinuesa</surname> <given-names>CG</given-names></name><name><surname>Ohler</surname> <given-names>U</given-names></name><name><surname>Standley</surname> <given-names>DM</given-names></name><name><surname>Landthaler</surname> <given-names>M</given-names></name><name><surname>Fujiwara</surname> <given-names>T</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms</article-title><source>Cell</source><volume>161</volume><fpage>1058</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.029</pub-id><pub-id pub-id-type="pmid">26000482</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mino</surname> <given-names>T</given-names></name><name><surname>Iwai</surname> <given-names>N</given-names></name><name><surname>Endo</surname> <given-names>M</given-names></name><name><surname>Inoue</surname> <given-names>K</given-names></name><name><surname>Akaki</surname> <given-names>K</given-names></name><name><surname>Hia</surname> <given-names>F</given-names></name><name><surname>Uehata</surname> <given-names>T</given-names></name><name><surname>Emura</surname> <given-names>T</given-names></name><name><surname>Hidaka</surname> <given-names>K</given-names></name><name><surname>Suzuki</surname> <given-names>Y</given-names></name><name><surname>Standley</surname> <given-names>DM</given-names></name><name><surname>Okada-Hatakeyama</surname> <given-names>M</given-names></name><name><surname>Ohno</surname> <given-names>S</given-names></name><name><surname>Sugiyama</surname> <given-names>H</given-names></name><name><surname>Yamashita</surname> <given-names>A</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translation-dependent unwinding of stem-loops by UPF1 licenses Regnase-1 to degrade inflammatory mRNAs</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>8838</fpage><lpage>8859</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz628</pub-id><pub-id pub-id-type="pmid">31329944</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller-McNicoll</surname> <given-names>M</given-names></name><name><surname>Neugebauer</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>How cells get the message: dynamic assembly and function of mRNA-protein complexes</article-title><source>Nature Reviews Genetics</source><volume>14</volume><fpage>275</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nrg3434</pub-id><pub-id pub-id-type="pmid">23478349</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muslin</surname> <given-names>AJ</given-names></name><name><surname>Tanner</surname> <given-names>JW</given-names></name><name><surname>Allen</surname> <given-names>PM</given-names></name><name><surname>Shaw</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine</article-title><source>Cell</source><volume>84</volume><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81067-3</pub-id><pub-id pub-id-type="pmid">8601312</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagami</surname> <given-names>H</given-names></name><name><surname>Sugiyama</surname> <given-names>N</given-names></name><name><surname>Mochida</surname> <given-names>K</given-names></name><name><surname>Daudi</surname> <given-names>A</given-names></name><name><surname>Yoshida</surname> <given-names>Y</given-names></name><name><surname>Toyoda</surname> <given-names>T</given-names></name><name><surname>Tomita</surname> <given-names>M</given-names></name><name><surname>Ishihama</surname> <given-names>Y</given-names></name><name><surname>Shirasu</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Large-scale comparative phosphoproteomics identifies conserved phosphorylation sites in plants</article-title><source>Plant Physiology</source><volume>153</volume><fpage>1161</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1104/pp.110.157347</pub-id><pub-id pub-id-type="pmid">20466843</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanki</surname> <given-names>K</given-names></name><name><surname>Fujii</surname> <given-names>M</given-names></name><name><surname>Shimokawa</surname> <given-names>M</given-names></name><name><surname>Matano</surname> <given-names>M</given-names></name><name><surname>Nishikori</surname> <given-names>S</given-names></name><name><surname>Date</surname> <given-names>S</given-names></name><name><surname>Takano</surname> <given-names>A</given-names></name><name><surname>Toshimitsu</surname> <given-names>K</given-names></name><name><surname>Ohta</surname> <given-names>Y</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Sugimoto</surname> <given-names>S</given-names></name><name><surname>Ishimaru</surname> <given-names>K</given-names></name><name><surname>Kawasaki</surname> <given-names>K</given-names></name><name><surname>Nagai</surname> <given-names>Y</given-names></name><name><surname>Ishii</surname> <given-names>R</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Sasaki</surname> <given-names>N</given-names></name><name><surname>Hibi</surname> <given-names>T</given-names></name><name><surname>Ishihara</surname> <given-names>S</given-names></name><name><surname>Kanai</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Somatic inflammatory gene mutations in human ulcerative colitis epithelium</article-title><source>Nature</source><volume>577</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1844-5</pub-id><pub-id pub-id-type="pmid">31853059</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neidel</surname> <given-names>S</given-names></name><name><surname>Ren</surname> <given-names>H</given-names></name><name><surname>Torres</surname> <given-names>AA</given-names></name><name><surname>Smith</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NF-κB activation is a turn on for vaccinia virus phosphoprotein A49 to turn off NF-κB activation</article-title><source>PNAS</source><volume>116</volume><fpage>5699</fpage><lpage>5704</lpage><pub-id pub-id-type="doi">10.1073/pnas.1813504116</pub-id><pub-id pub-id-type="pmid">30819886</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notredame</surname> <given-names>C</given-names></name><name><surname>Higgins</surname> <given-names>DG</given-names></name><name><surname>Heringa</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>T-Coffee: A novel method for fast and accurate multiple sequence alignment</article-title><source>Journal of Molecular Biology</source><volume>302</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2000.4042</pub-id><pub-id pub-id-type="pmid">10964570</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname> <given-names>LA</given-names></name><name><surname>Golenbock</surname> <given-names>D</given-names></name><name><surname>Bowie</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The history of Toll-like receptors - redefining innate immunity</article-title><source>Nature Reviews Immunology</source><volume>13</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/nri3446</pub-id><pub-id pub-id-type="pmid">23681101</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottmann</surname> <given-names>C</given-names></name><name><surname>Yasmin</surname> <given-names>L</given-names></name><name><surname>Weyand</surname> <given-names>M</given-names></name><name><surname>Veesenmeyer</surname> <given-names>JL</given-names></name><name><surname>Diaz</surname> <given-names>MH</given-names></name><name><surname>Palmer</surname> <given-names>RH</given-names></name><name><surname>Francis</surname> <given-names>MS</given-names></name><name><surname>Hauser</surname> <given-names>AR</given-names></name><name><surname>Wittinghofer</surname> <given-names>A</given-names></name><name><surname>Hallberg</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis</article-title><source>The EMBO Journal</source><volume>26</volume><fpage>902</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601530</pub-id><pub-id pub-id-type="pmid">17235285</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennington</surname> <given-names>KL</given-names></name><name><surname>Chan</surname> <given-names>TY</given-names></name><name><surname>Torres</surname> <given-names>MP</given-names></name><name><surname>Andersen</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions</article-title><source>Oncogene</source><volume>37</volume><fpage>5587</fpage><lpage>5604</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0348-3</pub-id><pub-id pub-id-type="pmid">29915393</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappsilber</surname> <given-names>J</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name><name><surname>Ishihama</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1896</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.261</pub-id><pub-id pub-id-type="pmid">17703201</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname> <given-names>P</given-names></name><name><surname>Markiel</surname> <given-names>A</given-names></name><name><surname>Ozier</surname> <given-names>O</given-names></name><name><surname>Baliga</surname> <given-names>NS</given-names></name><name><surname>Wang</surname> <given-names>JT</given-names></name><name><surname>Ramage</surname> <given-names>D</given-names></name><name><surname>Amin</surname> <given-names>N</given-names></name><name><surname>Schwikowski</surname> <given-names>B</given-names></name><name><surname>Ideker</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Research</source><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname> <given-names>N</given-names></name><name><surname>Imamura</surname> <given-names>H</given-names></name><name><surname>Ishihama</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Large-scale discovery of substrates of the human kinome</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>10503</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-46385-4</pub-id><pub-id pub-id-type="pmid">31324866</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname> <given-names>D</given-names></name><name><surname>Gable</surname> <given-names>AL</given-names></name><name><surname>Lyon</surname> <given-names>D</given-names></name><name><surname>Junge</surname> <given-names>A</given-names></name><name><surname>Wyder</surname> <given-names>S</given-names></name><name><surname>Huerta-Cepas</surname> <given-names>J</given-names></name><name><surname>Simonovic</surname> <given-names>M</given-names></name><name><surname>Doncheva</surname> <given-names>NT</given-names></name><name><surname>Morris</surname> <given-names>JH</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Jensen</surname> <given-names>LJ</given-names></name><name><surname>Mering</surname> <given-names>CV</given-names></name><name><surname>Von Mering</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname> <given-names>O</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pattern recognition receptors and inflammation</article-title><source>Cell</source><volume>140</volume><fpage>805</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Arima</surname> <given-names>Y</given-names></name><name><surname>Kamimura</surname> <given-names>D</given-names></name><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Takahashi</surname> <given-names>N</given-names></name><name><surname>Uehata</surname> <given-names>T</given-names></name><name><surname>Maeda</surname> <given-names>K</given-names></name><name><surname>Satoh</surname> <given-names>T</given-names></name><name><surname>Murakami</surname> <given-names>M</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phosphorylation-dependent Regnase-1 release from endoplasmic reticulum is critical in IL-17 response</article-title><source>Journal of Experimental Medicine</source><volume>216</volume><fpage>1431</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1084/jem.20181078</pub-id><pub-id pub-id-type="pmid">31072819</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>M</given-names></name><name><surname>Díaz-Muñoz</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RNA-binding proteins control gene expression and cell fate in the immune system</article-title><source>Nature Immunology</source><volume>19</volume><fpage>120</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0028-4</pub-id><pub-id pub-id-type="pmid">29348497</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uehata</surname> <given-names>T</given-names></name><name><surname>Iwasaki</surname> <given-names>H</given-names></name><name><surname>Vandenbon</surname> <given-names>A</given-names></name><name><surname>Matsushita</surname> <given-names>K</given-names></name><name><surname>Hernandez-Cuellar</surname> <given-names>E</given-names></name><name><surname>Kuniyoshi</surname> <given-names>K</given-names></name><name><surname>Satoh</surname> <given-names>T</given-names></name><name><surname>Mino</surname> <given-names>T</given-names></name><name><surname>Suzuki</surname> <given-names>Y</given-names></name><name><surname>Standley</surname> <given-names>DM</given-names></name><name><surname>Tsujimura</surname> <given-names>T</given-names></name><name><surname>Rakugi</surname> <given-names>H</given-names></name><name><surname>Isaka</surname> <given-names>Y</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation</article-title><source>Cell</source><volume>153</volume><fpage>1036</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.034</pub-id><pub-id pub-id-type="pmid">23706741</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Buuren</surname> <given-names>N</given-names></name><name><surname>Burles</surname> <given-names>K</given-names></name><name><surname>Schriewer</surname> <given-names>J</given-names></name><name><surname>Mehta</surname> <given-names>N</given-names></name><name><surname>Parker</surname> <given-names>S</given-names></name><name><surname>Buller</surname> <given-names>RM</given-names></name><name><surname>Barry</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>EVM005: an Ectromelia-Encoded protein with dual roles in NF-κB inhibition and virulence</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004326</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004326</pub-id><pub-id pub-id-type="pmid">25122471</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdoodt</surname> <given-names>B</given-names></name><name><surname>Benzinger</surname> <given-names>A</given-names></name><name><surname>Popowicz</surname> <given-names>GM</given-names></name><name><surname>Holak</surname> <given-names>TA</given-names></name><name><surname>Hermeking</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization of 14-3-3sigma dimerization determinants: requirement of homodimerization for inhibition of cell proliferation</article-title><source>Cell Cycle</source><volume>5</volume><fpage>2920</fpage><lpage>2926</lpage><pub-id pub-id-type="doi">10.4161/cc.5.24.3571</pub-id><pub-id pub-id-type="pmid">17172876</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname> <given-names>Y</given-names></name><name><surname>Xiao</surname> <given-names>H</given-names></name><name><surname>Affolter</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>TW</given-names></name><name><surname>Bulek</surname> <given-names>K</given-names></name><name><surname>Chaudhuri</surname> <given-names>S</given-names></name><name><surname>Carlson</surname> <given-names>D</given-names></name><name><surname>Hamilton</surname> <given-names>T</given-names></name><name><surname>Mazumder</surname> <given-names>B</given-names></name><name><surname>Stark</surname> <given-names>GR</given-names></name><name><surname>Thomas</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>10367</fpage><lpage>10375</lpage><pub-id pub-id-type="doi">10.1074/jbc.M807822200</pub-id><pub-id pub-id-type="pmid">19224918</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname> <given-names>AM</given-names></name><name><surname>Procter</surname> <given-names>JB</given-names></name><name><surname>Martin</surname> <given-names>DM</given-names></name><name><surname>Clamp</surname> <given-names>M</given-names></name><name><surname>Barton</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Jalview Version 2--a multiple sequence alignment editor and analysis workbench</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1189</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp033</pub-id><pub-id pub-id-type="pmid">19151095</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Long</surname> <given-names>L</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Dhungana</surname> <given-names>Y</given-names></name><name><surname>Lim</surname> <given-names>SA</given-names></name><name><surname>Guy</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>YD</given-names></name><name><surname>Qian</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Kc</surname> <given-names>A</given-names></name><name><surname>Saravia</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Doench</surname> <given-names>JG</given-names></name><name><surname>Geiger</surname> <given-names>TL</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy</article-title><source>Nature</source><volume>576</volume><fpage>471</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1821-z</pub-id><pub-id pub-id-type="pmid">31827283</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesche</surname> <given-names>H</given-names></name><name><surname>Henzel</surname> <given-names>WJ</given-names></name><name><surname>Shillinglaw</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Cao</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>MyD88: an adapter that recruits IRAK to the IL-1 receptor complex</article-title><source>Immunity</source><volume>7</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80402-1</pub-id><pub-id pub-id-type="pmid">9430229</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>D</given-names></name><name><surname>Marquis</surname> <given-names>K</given-names></name><name><surname>Pei</surname> <given-names>J</given-names></name><name><surname>Fu</surname> <given-names>SC</given-names></name><name><surname>Cağatay</surname> <given-names>T</given-names></name><name><surname>Grishin</surname> <given-names>NV</given-names></name><name><surname>Chook</surname> <given-names>YM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins</article-title><source>Bioinformatics</source><volume>31</volume><fpage>1357</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu826</pub-id><pub-id pub-id-type="pmid">25515756</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaffe</surname> <given-names>MB</given-names></name><name><surname>Rittinger</surname> <given-names>K</given-names></name><name><surname>Volinia</surname> <given-names>S</given-names></name><name><surname>Caron</surname> <given-names>PR</given-names></name><name><surname>Aitken</surname> <given-names>A</given-names></name><name><surname>Leffers</surname> <given-names>H</given-names></name><name><surname>Gamblin</surname> <given-names>SJ</given-names></name><name><surname>Smerdon</surname> <given-names>SJ</given-names></name><name><surname>Cantley</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The structural basis for 14-3-3:phosphopeptide binding specificity</article-title><source>Cell</source><volume>91</volume><fpage>961</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80487-0</pub-id><pub-id pub-id-type="pmid">9428519</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>Mei</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Jiao</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCF<sup>β-TRCP</sup>-Mediated Degradation of NRF2 in Pancreatic Cancer</article-title><source>Molecular Therapy - Nucleic Acids</source><volume>19</volume><fpage>974</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2019.11.035</pub-id><pub-id pub-id-type="pmid">32036249</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yashiroda</surname> <given-names>Y</given-names></name><name><surname>Yoshida</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Nucleo-Cytoplasmic Transport of Proteins as a Target for Therapeutic Drugs</article-title><source>Current Medicinal Chemistry</source><volume>10</volume><fpage>741</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.2174/0929867033457791</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasmin</surname> <given-names>L</given-names></name><name><surname>Jansson</surname> <given-names>AL</given-names></name><name><surname>Panahandeh</surname> <given-names>T</given-names></name><name><surname>Palmer</surname> <given-names>RH</given-names></name><name><surname>Francis</surname> <given-names>MS</given-names></name><name><surname>Hallberg</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Delineation of exoenzyme S residues that mediate the interaction with 14-3-3 and its biological activity</article-title><source>FEBS Journal</source><volume>273</volume><fpage>638</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2005.05100.x</pub-id><pub-id pub-id-type="pmid">16420486</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>H</given-names></name><name><surname>Arron</surname> <given-names>JR</given-names></name><name><surname>Lamothe</surname> <given-names>B</given-names></name><name><surname>Cirilli</surname> <given-names>M</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Shevde</surname> <given-names>NK</given-names></name><name><surname>Segal</surname> <given-names>D</given-names></name><name><surname>Dzivenu</surname> <given-names>OK</given-names></name><name><surname>Vologodskaia</surname> <given-names>M</given-names></name><name><surname>Yim</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>K</given-names></name><name><surname>Singh</surname> <given-names>S</given-names></name><name><surname>Pike</surname> <given-names>JW</given-names></name><name><surname>Darnay</surname> <given-names>BG</given-names></name><name><surname>Choi</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Distinct molecular mechanism for initiating TRAF6 signalling</article-title><source>Nature</source><volume>418</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature00888</pub-id><pub-id pub-id-type="pmid">12140561</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokogawa</surname> <given-names>M</given-names></name><name><surname>Tsushima</surname> <given-names>T</given-names></name><name><surname>Noda</surname> <given-names>NN</given-names></name><name><surname>Kumeta</surname> <given-names>H</given-names></name><name><surname>Enokizono</surname> <given-names>Y</given-names></name><name><surname>Yamashita</surname> <given-names>K</given-names></name><name><surname>Standley</surname> <given-names>DM</given-names></name><name><surname>Takeuchi</surname> <given-names>O</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Inagaki</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structural basis for the regulation of enzymatic activity of Regnase-1 by domain-domain interactions</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>22324</elocation-id><pub-id pub-id-type="doi">10.1038/srep22324</pub-id><pub-id pub-id-type="pmid">26927947</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71966.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><role>Reviewing Editor</role><aff><institution>McGill University</institution><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Stoecklin</surname><given-names>Georg</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.07.15.452458">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.07.15.452458v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study describes a new mechanism by which Regnase-1 is inhibited upon immune activation, which mediates the efficient synthesis of inflammatory mediators whose mRNAs are normally degraded by Regnase-1. The study report a novel interaction of Regnase-1 with 14-3-3. This provides an alternative mechanism by which inflammatory mRNAs are upregulated by inhibiting degradation via Regnase-1.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;IRAK1-dependent Regnase-1-14-3-3 complex formation controls Regnase-1-mediated mRNA decay&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Carla Rothlin as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Georg Stoecklin (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Most of the reviewers' excellent suggestions are intended for future experiments, which are not required for this paper. However, some experiments lack necessary controls and others do not adequately support the conclusions. The comments listed before must be addressed, and some statements (see specific reviewers' comments) need to be changed or deleted:</p><p>1) Figure 1C. Input control on the same blots as the IPs are run ought to be shown, and include a negative control blot (e.g. actin) as well.</p><p>2) Figure 1D. It is important to show a longer exposure of the Regnase1 blots for both the input blot and the blot from the immunoprecipitation.</p><p>3) You show that IL-6 mRNA levels are similar in Regnase-1 WT and S513A mutant cells (Figure 4D-F). This notion is difficult to reconcile with the author's finding that 14-3-3 binding to Regnase-1 prevents it from binding to and inducing the degradation of IL-6 mRNA. This discrepancy should be discussed critically. Moreover, previous studies have shown that changes in mRNA stability are not necessarily reflected by changes in mRNA steady-state levels, since they can be buffered by altered transcription (see e.g. Singh et al., 2019; PMID: 31116665). Therefore, mRNA degradation rates should be measured directly by actinomycin D chase or similar experiments.</p><p>4) You claim &quot;that 14-3-3 inhibits Regnase-1-mRNA binding, thereby abrogating Regnase-1-mediated mRNA degradation&quot;. However, this is only shown for IL-6 mRNA (Figure 5G). Since this is a key result of the study, you should also test other targets of Regnase-1 so as to generalize their finding.</p><p>5) Figure 5A. Expression levels of exogenous Regnase-1 mutants ought to be shown.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The data suggest that IRAK1/2 may directly phosphorylate Regnase-1 (Fig.2G-I), although the authors do not address this question either experimentally or in the discussion. Do the authors have evidence that Regnase-1 is a direct target of IRAK1/2? Minimally, the authors should discuss this point and assess whether the identified phosphorylation sites conform to consensus IRAK target motifs.</p><p>The evidence for mutually exclusive binding of Regnase-1 to bTRCP or 14-3-3 is rather indirect, through the analysis of Regnase-1 phosphorylation status and phosphomutants (Fig.3). This point could be strengthened by competition assays, in which expressing increasing amounts of one protein should weaken the interaction with the other.</p><p>Figure 2G: The figure legend states that HeLa cells were &quot;stimulated with IL-1b (10 ng/ml) for 4 hours&quot;. Is this correct? The blot shows the faster migrating Regnase-1 band and no interaction with 14-3-3 unless IRAK1/2 is overexpressed, which corresponds to the situation in unstimulated cells.</p><p>Figure 4A-C: As a direct assessment of Regnase-1 protein stability, the authors could conduct cycloheximide chase assays in Wt/Wt and S513A/S513A cells.</p><p>Figure 4 and 5: The figure legends say &quot;…bars represent mean values of biological replicates (n=3)… similar results were obtained from at least two independent experiments&quot;. It is unclear what is meant by these two different statements.</p><p>lines 189 and 195: should refer to Figure 3, not 2.</p><p>line 231: should refer to Figure 4D-I</p><p>Figure 4J-K: figure legend should say Regnase-1 instead of Reganse-1</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Line 26: &quot;both interactions occur in a mutually exclusive manner, underscoring the importance of modulating Regnase-1's activity&quot;</p><p>I don't think the fact that the interactions are mutually exclusive underscores the importance of modulating Regnase activity. That Regnase-1 can be inactivated by two different, and perhaps partially redundant, mechanisms underscores the importance of modulating Regnase activity.</p><p>Line 138: &quot;14-3-3 specifically binds to phosphorylated Regnase-1&quot;</p><p>The authors concluded that 14-3-3 binds to phosphorylated S494 and S513 of Regnase-1 but direct binding between Regnase-1 and 14-3-3 and their binding sites are not shown. The authors would need to perform experiments to address this point, or otherwise rewrite the manuscript to correctly interpret the data.</p><p>In Figure 2A, the IL-1β-induced interaction between 14-3-3 and Reg1 is reduced by phosphatase treatment, but it still appears relatively strong. Therefore, it is not possible to say from this IP that 14-3-3 binds specifically to phospho-Reg1. Since the band shift is abolished by PP in Figure 2A, it looks like 14-3-3 may still bind to non-phosphorylated Reg1, but perhaps with lower affinity.</p><p>Line 190-191: &quot;We next checked the phosphorylation status of βTRCP-bound and 14-3-3-bound Regnase-1&quot;</p><p>This sentence seems to be in the wrong place. It appears to refer to Figure 3A/B, but it comes before 3C.</p><p>Line 195: &quot;βTRCP-ΔF-bound Regnase-1 migrated faster than 14-3-3-bound Regnase-1 (Figure 2C-D)&quot;</p><p>Please clarify why Figure2C and 2D are referenced here. In particular, Figure 2C shows residues which are phosphorylated in IL-1B-stimulated cells.</p><p>Line 211: &quot;Regnase-1 showed slow migration and was able to associate with 14-3-3&quot;</p><p>Based on the band shift in Figure 4A, it is a reasonable assumption that the newly synthesized Reg1 was phosphorylated and therefore it could bind to 14-3-3, but the figure does not show that it was associated with 14-3-3. This should be made clear.</p><p>Figure 5A, Expression levels of exogenous Regnase-1 mutants need to be shown. It is considered that the expression levels must be the same at initial condition.</p><p>Line 231: &quot;Figure 3D-I&quot; should refer to &quot;Figure 4D-I&quot;</p><p>Line 248: &quot;These results suggest that the phosphorylation at S513 and the following association with 14-3-3 nullifies Regnase-1's ability in degrading target mRNAs&quot;</p><p>From the data presented up to this point in the manuscript, it is not possible to say whether 14-3-3 binding or S513 phosphorylation alone prevents Reg1 from degrading Il6 mRNA. The following data presented in Figure 5 does address this.</p><p>Line 262: The experiments using Reg-1ExoSx2 are valid only if interacting site of 14-3-3 with Regnase-1 is the same as that with ExoS. The authors should clearly mention this point or show that 14-3-3 binds to Regnase-1 with its phosphopeptide binding groove.</p><p>Line 278: In Figure 5D, the difference between Il6 only and Il6+ExoSx2 looks like it could be significant. What is the P value?</p><p>Line 335-336: &quot;Analysis of Regnase-1S513A/S513A mice revealed that 14-3-3-mediated abrogation of Regnase-1 can be compensated by the degradation of Regnase-1&quot;</p><p>The data from the S513A mutants doesn't show that degradation compensates for 14-3-3-mediated block of Reg1 function. It shows that not all Reg1 is bound to 14-3-3, and only the non-14-3-3-bound Reg1 regulates mRNA stability.</p><p>The authors could say that the absence of 14-3-3-mediated abrogation of Reg1 in the S513A mutant cells may be compensated for by increased degradation. But to be sure of this, the authors should demonstrate that translation is not affected.</p><p>Line 347: &quot;compensation by βTRCP-mediated regulation, which we observed in Regnase-1S513A/S513A mice&quot;</p><p>Could the authors demonstrate that this is definitely βTRCP-mediated regulation? If the mutant βTRCP used in Figure 2 acts as a dominant-negative, perhaps overexpression in S513A mutant cells could show this?</p><p>Line 369-370: &quot;βTRCP is likely to recognize 14-3-3-free Regnase-1, indicating that 14-3-3 inhibits Regnase-1-βTRCP interaction&quot;</p><p>The wording of this sentence suggests that 14-3-3-Reg1 binding takes precedence over βTRCP-Reg1. Is there any reason to assume that this is true? If binding is mutually exclusive, as suggested by Figure 3C, could βTRCP also inhibit the 14-3-3-Reg1 interaction? The authors should clarify here whether the interaction of Reg1 with 14-3-3 is likely to be dominant over the interaction with βTRCP.</p><p>Figure 1C suggests that βTRCP-Reg1 binding peaks sooner after IL-1β stimulation than 14-3-3-Reg1 binding. Could this mean that βTRCP binds to Reg1 first, before 14-3-3?</p><p>Line 387: &quot;evolutionally conserved&quot; should be &quot;evolutionarily conserved&quot;</p><p><italic>Reviewer #4 (Recommendations for the authors):</italic></p><p>1. In Figure 1C, the co-immunoprecipitation Regnase1 with myc-tagged 14-3-3epsilon doesn't look exceptionally robust, especially when seeing the original blot provided as source data. It's currently hard to tell whether this represents a small amount of endogenous Regnase1 or a larger percentage co-precipitating. What would help to improve the strength of this figure is to include an input control on the same blots as the IPs are run, and to include a negative control blot (e.g. actin) as well. This will help to validate the specificity of the interaction.</p><p>2. For Figure 1D, are the authors able to show a longer exposure of the Regnase1 blots as well? For both the input blot and the blot from the immunoprecipitation. This would help to strengthen their conclusion that R848 and CpG DNA stimuli promote the interaction between 14-3-3 and Regnase1.</p><p>3. The authors conclude that the interaction of Regnase1 and 14-3-3 is mediated by IRAK-dependent phosphorylation. As these experiments were all conducted by overexpression of IRAK1 or 2, it would significantly strengthen their conclusion if they carried out some knockdown experiments where they deplete endogenous IRAK1/2. Does this abolish the 14-3-3 interaction with Regnase1 in IL-1B treated cells?</p><p>4. While I agree with the authors that their data support different phosphorylated serine residues supporting interactions with either 14-3-3 or TRCP, I don't think that their data specifically support mutually exclusive interactions between the two. A convincing competition experiment to test this may be to express both 14-3-3 and TRCP at different levels along with Regnase1. This would allow them to immunopreciptate a tagged Regnase 1 and see if, for example, increasing TRCP expression increases its association with Regnase1, while decreasing the association of 14-3-3 with Regnase1.</p><p>5. For Figure 5G, the authors should also test specific Serine-to-Alanine mutants to see if they impact RNA binding. This could be accomplished with a mutant that cannot bind TRCP (to keep it stable), and compare it to a mutant that cannot bind both TRCP and 14-3-3. This would allow the authors to make conclusions on a Regnase1 mutant that did not contain additional bacterial stretches to it, which could bind to proteins other than 14-3-3 that they don't know about.</p><p>6. Similarly, the final conclusion of the manuscript is that 14-3-3 binding to Regnase1 localizes to the nucleus. However, this is based on Regnase mutants that utilize bacterial stretches that bind 14-3-3 proteins (and potentially other proteins as well). To strengthen their data, the authors should utilize a Regnase mutant that cannot bind to TRCP and/or contains mutations of serine residues such that it cannot bind 14-3-3 proteins. These mutants could then be used to test if nuclear localization is impaired without adding additional bacterial protein stretches to it.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71966.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Most of the reviewers' excellent suggestions are intended for future experiments, which are not required for this paper. However, some experiments lack necessary controls and others do not adequately support the conclusions. The comments listed before must be addressed, and some statements (see specific reviewers' comments) need to be changed or deleted:</p></disp-quote><p>We thank the reviewers and editors for valuable suggestions. We revised the manuscript accordingly as indicated in our responses to the reviewers’ comments below.</p><disp-quote content-type="editor-comment"><p>1) Figure 1C. Input control on the same blots as the IPs are run ought to be shown, and include a negative control blot (e.g. actin) as well.</p></disp-quote><p>We thank the reviewer for the advice. According to the reviewer’s suggestion, we loaded the input and IP samples used in Figure 1C on the same gel and blotted membranes using anti-Actin antibody as well as anti-Regnase-1 antibody (new Figure 1—figure supplement 1). Compared with input samples, only trace amounts of Actin bands were detected in every IP-sample including 14-3-3ε negative. This is probably because of non-specific binding between Actin and Dynabeads or protein G used for immunoprecipitation. In contrast, strong Regnase-1 bands were detected in IL-1β-stimulated (2 or 4 hours) HA-14-3-3ε transfected samples, but not in IL-1β-stimulated (4 hours) HA-14-3-3ε negative sample. Therefore, these results further support our finding that the binding between Regnase-1 and 14-3-3 specifically induced by IL-1β stimulation.</p><disp-quote content-type="editor-comment"><p>2) Figure 1D. It is important to show a longer exposure of the Regnase1 blots for both the input blot and the blot from the immunoprecipitation.</p></disp-quote><p>We thank the reviewer for the constructive criticism. Since we acquired the image with only one exposure time setting (16-bit), we adjusted the range of brightness to show the bands at two different brightness level (8-bit) (new Figure 1D). These data further confirm that the MyD88-dependent signaling activated downstream of TLR/IL-1R induces the interaction between Regnase-1 and 14-3-3.</p><disp-quote content-type="editor-comment"><p>3) You show that IL-6 mRNA levels are similar in Regnase-1 WT and S513A mutant cells (Figure 4D-F). This notion is difficult to reconcile with the author's finding that 14-3-3 binding to Regnase-1 prevents it from binding to and inducing the degradation of IL-6 mRNA. This discrepancy should be discussed critically. Moreover, previous studies have shown that changes in mRNA stability are not necessarily reflected by changes in mRNA steady-state levels, since they can be buffered by altered transcription (see e.g. Singh et al., 2019; PMID: 31116665). Therefore, mRNA degradation rates should be measured directly by actinomycin D chase or similar experiments.</p></disp-quote><p>We thank the reviewer for the suggestion. To check mRNA degradation rates, we stimulated MEFs with IL-1β for 4 hours, at which time point the protein level of Regnase-1 shows huge difference between <italic>Regnase-1</italic><sup>WT/WT</sup> and <italic>Regnase-1</italic><sup>S513A/S513A</sup> cells, and added Actinomycin D. We found that degradation rates of Regnase-1 target mRNAs such as <italic>Il6</italic>, <italic>Regnase-1</italic>, and <italic>Nfkbiz</italic> were comparable <italic>Regnase-1</italic><sup>WT/WT</sup> and <italic>Regnase-1</italic><sup>S513A/S513A</sup> MEFs (now shown as new Figure 4—figure supplement 4).</p><disp-quote content-type="editor-comment"><p>4). You claim &quot;that 14-3-3 inhibits Regnase-1-mRNA binding, thereby abrogating Regnase-1-mediated mRNA degradation&quot;. However, this is only shown for IL-6 mRNA (Figure 5G). Since this is a key result of the study, you should also test other targets of Regnase-1 so as to generalize their finding.</p></disp-quote><p>We thank the reviewer for the constructive criticism. Since we previously identified binding targets of Regnase-1 in HeLa cells (Mino et al., 2015), we checked if ExoSx2 mutation also abrogates the binding between Regnase-1 and some of these target mRNAs including <italic>PTGS2</italic>, <italic>NFKBIZ</italic>, <italic>REGNASE-1</italic>, <italic>CXCL1</italic>, <italic>CXCL2</italic>, <italic>CXCL3</italic>, <italic>MAFA</italic>, and <italic>NFKBID</italic>. As shown in new Figure 5—figure supplement 2, Regnase-1-ExoSx2 failed to bind with all Regnase-1 target mRNAs tested, in addition to <italic>IL6</italic> shown in Figure 5H. These results further confirm that 14-3-3 inhibits Regnase-1-mRNA binding.</p><disp-quote content-type="editor-comment"><p>5). Figure 5A. Expression levels of exogenous Regnase-1 mutants ought to be shown.</p></disp-quote><p>We thank the reviewer for the comment. Since the majority of overexpressed Regnase-1 are not affected by IL-1β-mediated phosphorylation (e.g., Figure 2D, 3A, and 3B), we reduced the amount of transfected Regnase-1 as much as possible in former Figure 5A (Figure 5B) in order to observe the effect of each SA mutation on the activity of Regnase-1. However, such low expressed Regnase-1 was undetectable in immunoblotting with tag antibody. Therefore, to check the expression level of low expressed Regnase-1, we performed immunoblot analysis using anti-Regnase-1 antibody, which has strong affinity to Regnase-1, using <italic>REGNASE-1</italic> KO HeLa cells transfected with Regnase-1-WT and SA mutants (new Figure 5A). The expression level of each exogenous Regnase-1 was comparable without IL-1β stimulation. Nevertheless, the S513A mutant Regnase-1 showed decreased expression 2 or 4 hours after IL-1β stimulation, consistent with our observation in <italic>Regnase-1</italic><sup>S513A/S513A</sup> MEFs (Figure 4A). On the other hand, S435/439/513A mutant showed higher expression compared to S513A mutant.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The data suggest that IRAK1/2 may directly phosphorylate Regnase-1 (Fig.2G-I), although the authors do not address this question either experimentally or in the discussion. Do the authors have evidence that Regnase-1 is a direct target of IRAK1/2? Minimally, the authors should discuss this point and assess whether the identified phosphorylation sites conform to consensus IRAK target motifs.</p></disp-quote><p>We thank the reviewer for the suggestion. A previous kinome study comprehensively identifying kinase substrates suggests that the sequence motifs of target phosphorylation site of IRAK1 is pSxV and KxxxpS (Sugiyama et al., 2019; PMID: 31324866). However, these sequences do not match the sequence at S494 and S513 of Regnase-1 (Figure 2F). We speculate other kinases are activated by IRAK1/2 and phosphorylate Regnase-1 at S494 and S513, although we cannot exclude the possibility that Regnase-1 is directly phosphorylated by IRAK1/2 at S494 and S513. We added this point in the Discussion section.</p><disp-quote content-type="editor-comment"><p>The evidence for mutually exclusive binding of Regnase-1 to bTRCP or 14-3-3 is rather indirect, through the analysis of Regnase-1 phosphorylation status and phosphomutants (Fig.3). This point could be strengthened by competition assays, in which expressing increasing amounts of one protein should weaken the interaction with the other.</p></disp-quote><p>We thank the reviewer for the criticism. As the other reviewers point out, the wording of &quot;mutually exclusive&quot; might mislead readers. As shown in Figure 3C and 3D, βTRCP recognizes 14-3-3-free Regnase-1 but not slowly migrating Regnase-1, which is the binding target of 14-3-3. In addition, Regnase-1-S513A mutant is unstable after IL-1β or LPS stimulation (Figure 4A, 4B, 4C, and 5A). These results suggest that 14-3-3 stabilizes Regnase-1 by preventing the formation of Regnase-1-βTRCP complex. However, we have not shown the data indicating βTRCP inhibits Regnase-1-14-3-3 association. We therefore corrected the sentences about the relationship between Regnase-1-14-3-3 complex and Regnase-1-βTRCP complex throughout the manuscript. These binding events occur independently and not sequentially, and 14-3-3 inhibits Regnase-1-βTRCP binding. We did not investigate whether βTRCP affects Regnase-1-14-3-3 interaction or not because once proteins (substrates of SCF complex) bind to βTRCP, they get ubiquitinated and degraded via proteasome system.We agree with the reviewer that the competition assay will help to clarify the detailed mechanism how 14-3-3 inhibits Regnase-1-βTRCP binding. However, we feel thein vitroassay is beyond the scope of this study. 14-3-3 mediated abrogation of the nuclear-cytoplasmic shuttling of Regnase-1 might be one of clues to answer this question.</p><disp-quote content-type="editor-comment"><p>Figure 2G: The figure legend states that HeLa cells were &quot;stimulated with IL-1b (10 ng/ml) for 4 hours&quot;. Is this correct? The blot shows the faster migrating Regnase-1 band and no interaction with 14-3-3 unless IRAK1/2 is overexpressed, which corresponds to the situation in unstimulated cells.</p></disp-quote><p>We thank the reviewer for pointing out our mistake in the Figure legend. We did not stimulate cells in the experiment shown in Figure 2G. We corrected the legend for Figure 2G as follows: “(G) Immunoblot analysis of immunoprecipitates (IP: Myc) and WCL from HeLa cells transiently expressing Myc-14-3-3ε, HA-IRAK1/2, and FLAG-Regnase-1-WT or indicated mutants.”</p><disp-quote content-type="editor-comment"><p>Figure 4A-C: As a direct assessment of Regnase-1 protein stability, the authors could conduct cycloheximide chase assays in Wt/Wt and S513A/S513A cells.</p></disp-quote><p>We thank the reviewer for the advice. According to the reviewer’s advice, we assessed Regnase-1 protein stability by adding cycloheximide (CHX) (new Figure 4—figure supplement 2). Since both WT and S513A Regnase-1 degraded rapidly (30 minutes) after the stimulation with IL-1β or LPS (Figure 4A-C), we added CHX and LPS at the same time and collected cell lysates at earlier time points (10, 20, and 30 minutes after the stimulation). We found that Regnase-1 S513A mutant degraded more quickly than WT Regnase-1 in PECs in response to LPS stimulation (Figure 4—figure supplement 2). This is because phosphorylated WT Regnase-1 (upper bands), which was not observed in <italic>Regnase-1</italic><sup>S513A/S513A</sup>, persisted after the stimulation. This result further supports our finding that S513A mutation destabilizes Regnase-1 protein.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Line 26: &quot;both interactions occur in a mutually exclusive manner, underscoring the importance of modulating Regnase-1's activity&quot;</p><p>I don't think the fact that the interactions are mutually exclusive underscores the importance of modulating Regnase activity. That Regnase-1 can be inactivated by two different, and perhaps partially redundant, mechanisms underscores the importance of modulating Regnase activity.</p></disp-quote><p>We thank the reviewer for the criticism. As the reviewer pointed out, the abstract lacks logic to some extent because of the order of sentences. According to the reviewer’s comment, we revised the abstract section.</p><disp-quote content-type="editor-comment"><p>Line 138: &quot;14-3-3 specifically binds to phosphorylated Regnase-1&quot;</p><p>The authors concluded that 14-3-3 binds to phosphorylated S494 and S513 of Regnase-1 but direct binding between Regnase-1 and 14-3-3 and their binding sites are not shown. The authors would need to perform experiments to address this point, or otherwise rewrite the manuscript to correctly interpret the data.</p><p>In Figure 2A, the IL-1β-induced interaction between 14-3-3 and Reg1 is reduced by phosphatase treatment, but it still appears relatively strong. Therefore, it is not possible to say from this IP that 14-3-3 binds specifically to phospho-Reg1. Since the band shift is abolished by PP in Figure 2A, it looks like 14-3-3 may still bind to non-phosphorylated Reg1, but perhaps with lower affinity.</p></disp-quote><p>We thank the reviewer for the advice. 14-3-3 is well known to directly bind to phosphorylated proteins and the binding motif of 14-3-3 partially overlaps with the sequences surrounding S494 and S513 of Regnase-1 (Figure 2F). Furthermore, the mutations in S494 and S513 abrogated the interaction between Regnase-1 and 14-3-3 (Figure 2D), indicating that the phosphorylation of both sites is critical for Regnase-1-14-3-3 interaction. These results strongly suggest that the 14-3-3 dimer directly recognizes phosphorylated Regnase-1 at both S494 and S513 at least under IL-1β-, MyD88-dependent TLR ligand-, or IL-17A-stimulation. We added this argument in the Discussion section.</p><p>In Figure 2A-B, we treated the samples with λPP after the immunoprecipitation with HA-14-3-3ε, indicating that Regnase-1 is supposed to be detected in the precipitated samples irrespective of the λPP treatment. Indeed, the amounts of Regnase-1 co-precipitated with 14-3-3ε was not altered by the λPP treatment (Figure 2A). However, the λPP treatment changed the mobility of Regnase-1 in the immunoblot analysis and made Regnase-1 migrate faster. These results demonstrate that 14-3-3 associates phosphorylated, but not unphosphorylated, Regnase-1.</p><disp-quote content-type="editor-comment"><p>Line 190-191: &quot;We next checked the phosphorylation status of βTRCP-bound and 14-3-3-bound Regnase-1&quot;</p><p>This sentence seems to be in the wrong place. It appears to refer to Figure 3A/B, but it comes before 3C.</p></disp-quote><p>We thank the reviewer for the advice. According to the reviewer’s suggestion, we revised the sentence as follows: &quot;We next compared the phosphorylation status of βTRCP-bound and 14-3-3-bound Regnase-1.&quot;</p><disp-quote content-type="editor-comment"><p>Line 211: &quot;Regnase-1 showed slow migration and was able to associate with 14-3-3&quot;</p><p>Based on the band shift in Figure 4A, it is a reasonable assumption that the newly synthesized Reg1 was phosphorylated and therefore it could bind to 14-3-3, but the figure does not show that it was associated with 14-3-3. This should be made clear.</p></disp-quote><p>We thank the reviewer for the concern. To clarify the point raised by the reviewer, we revised the sentences as follows: &quot; Notably, most of the newly synthesized Regnase-1 showed slow migration, consistent with the immunoprecipitation experiment using HeLa cells or RAW264.7 cells shown in Figure 1C and 1D… Interestingly, the amount of Regnase-1 at lower bands, which are not the binding target of 14-3-3 (Figure 2A), was comparable between WT and <italic>Regnase-1</italic><sup>S513A/S513A</sup> at corresponding time points.&quot;</p><disp-quote content-type="editor-comment"><p>Figure 5A, Expression levels of exogenous Regnase-1 mutants need to be shown. It is considered that the expression levels must be the same at initial condition.</p></disp-quote><p>This comment was found in the Essential Revisions and was already addressed.</p><disp-quote content-type="editor-comment"><p>Line 248: &quot;These results suggest that the phosphorylation at S513 and the following association with 14-3-3 nullifies Regnase-1's ability in degrading target mRNAs&quot;</p><p>From the data presented up to this point in the manuscript, it is not possible to say whether 14-3-3 binding or S513 phosphorylation alone prevents Reg1 from degrading Il6 mRNA. The following data presented in Figure 5 does address this.</p></disp-quote><p>We thank the reviewer for the comment. We agree with the concern and corrected the sentences as follows:</p><p>&quot;These results imply that the phosphorylation at S513 and the following association with 14-3-3 nullifies Regnase-1’s ability in degrading target mRNAs&quot;</p><disp-quote content-type="editor-comment"><p>Line 262: The experiments using Reg-1ExoSx2 are valid only if interacting site of 14-3-3 with Regnase-1 is the same as that with ExoS. The authors should clearly mention this point or show that 14-3-3 binds to Regnase-1 with its phosphopeptide binding groove.</p></disp-quote><p>We thank the reviewer for the concern. As we mentioned above, it is quite plausible that the 14-3-3 dimer directly recognizes phosphorylated S494 and S513 of Regnase-1. In this regard, we believe that the experiments using Regnase-1-ExoSx2 are meaningful.</p><disp-quote content-type="editor-comment"><p>Line 278: In Figure 5D, the difference between Il6 only and Il6+ExoSx2 looks like it could be significant. What is the P value?</p></disp-quote><p>The P value between Il6 only and Il6+ExoSx2 is 0.00048. Since we overexpressed Regnase-1-ExoSx2, we speculate this difference is because some of 14-3-3-free ExoSx2 mutant functioned to suppress Il6 expression.</p><disp-quote content-type="editor-comment"><p>Line 335-336: &quot;Analysis of Regnase-1S513A/S513A mice revealed that 14-3-3-mediated abrogation of Regnase-1 can be compensated by the degradation of Regnase-1&quot;</p><p>The data from the S513A mutants doesn't show that degradation compensates for 14-3-3-mediated block of Reg1 function. It shows that not all Reg1 is bound to 14-3-3, and only the non-14-3-3-bound Reg1 regulates mRNA stability.</p><p>The authors could say that the absence of 14-3-3-mediated abrogation of Reg1 in the S513A mutant cells may be compensated for by increased degradation. But to be sure of this, the authors should demonstrate that translation is not affected.</p></disp-quote><p>We thank the reviewer for the concern. Reviewer #2 also suggests that we needed to make sure if S513A mutation affects protein stability of Regnase-1. According to the reviewers’ suggestion, we examined the stability of Regnase-1 by treating the cells with CHX. As shown in new Figure 4—figure supplement 2, we successfully show that Regnase-1-S513A is more unstable than WT after LPS and CHX treatment.</p><disp-quote content-type="editor-comment"><p>Line 347: &quot;compensation by βTRCP-mediated regulation, which we observed in Regnase-1S513A/S513A mice&quot;</p><p>Could the authors demonstrate that this is definitely βTRCP-mediated regulation? If the mutant βTRCP used in Figure 2 acts as a dominant-negative, perhaps overexpression in S513A mutant cells could show this?</p></disp-quote><p>We thank the reviewer for the concern. As shown in new Figure 5A, additional S435/439A mutation, which abrogates Regnase-1-βTRCP binding, stabilized Regnase-1-S513A protein after IL-1β stimulation. The result indicates that the degradation of Regnase-1-S513A in response to IL-1β stimulation is dependent on βTRCP. Therefore, we revised the sentence as follows: &quot;…compensation by βTRCP-mediated regulation, which we observed in Regnase-1S513A/S513A mice and HeLa cells transiently expressing Regnase-1-S513A and S435/439/513A.&quot;</p><disp-quote content-type="editor-comment"><p>Line 369-370: &quot;βTRCP is likely to recognize 14-3-3-free Regnase-1, indicating that 14-3-3 inhibits Regnase-1-βTRCP interaction&quot;</p><p>The wording of this sentence suggests that 14-3-3-Reg1 binding takes precedence over βTRCP-Reg1. Is there any reason to assume that this is true? If binding is mutually exclusive, as suggested by Figure 3C, could βTRCP also inhibit the 14-3-3-Reg1 interaction? The authors should clarify here whether the interaction of Reg1 with 14-3-3 is likely to be dominant over the interaction with βTRCP.</p><p>Figure 1C suggests that βTRCP-Reg1 binding peaks sooner after IL-1β stimulation than 14-3-3-Reg1 binding. Could this mean that βTRCP binds to Reg1 first, before 14-3-3?</p></disp-quote><p>We thank the reviewer for the concern. As the reviewer pointed out, both Regnase-1-WT and S513A undergo βTRCP-mediated degradation within 30 minutes after IL-1β or LPS stimulation (Figure 4A-C) (Iwasaki et al., 2011). This is probably because of the higher activity of IKKs at the early time point compared to later time points (Iwasaki et al., 2011). We think that Regnase-1 can also associate with 14-3-3 at such an early time point because Regnase-1-WT showed strong phosphorylated band 30 minutes after LPS stimulation when protein degradation was inhibited by MG-132 (Figure 4C). Moreover, we found that Regnase-1 phosphorylation, which was not observed in <italic>Regnase-1</italic><sup>S513A/S513A</sup>, occurred 10 minutes after LPS stimulation (new Figure 4—figure supplement 2). These data indicate that Regnase-1 can be phosphorylated at S513 at the early time point after IL-1β or LPS stimulation. Since 14-3-3 does not covalently bind to Regnase-1, it is plausible that Regnase-1-14-3-3 binding is a reversible reaction, while protein degradation of Regnase-1 is irreversible. We believe this is the reason why 14-3-3 failed to protect Regnase-1 from βTRCP-mediated protein degradation at the early time point.</p><p>Reviewer #2 also pointed out the wording, &quot;mutually exclusive&quot;, might not appropriate. As we described in our response to the comment of Reviewer #2, we have corrected the wording.</p><disp-quote content-type="editor-comment"><p>Reviewer #4 (Recommendations for the authors):</p><p>Major points to be addressed:</p><p>1. In Figure 1C, the co-immunoprecipitation Regnase1 with myc-tagged 14-3-3epsilon doesn't look exceptionally robust, especially when seeing the original blot provided as source data. It's currently hard to tell whether this represents a small amount of endogenous Regnase1 or a larger percentage co-precipitating. What would help to improve the strength of this figure is to include an input control on the same blots as the IPs are run, and to include a negative control blot (e.g. actin) as well. This will help to validate the specificity of the interaction.</p></disp-quote><p>This comment was found in the Essential Revisions and was already addressed.</p><disp-quote content-type="editor-comment"><p>2. For Figure 1D, are the authors able to show a longer exposure of the Regnase1 blots as well? For both the input blot and the blot from the immunoprecipitation. This would help to strengthen their conclusion that R848 and CpG DNA stimuli promote the interaction between 14-3-3 and Regnase1.</p></disp-quote><p>This comment was found in the Essential Revisions and was already addressed.</p><disp-quote content-type="editor-comment"><p>3. The authors conclude that the interaction of Regnase1 and 14-3-3 is mediated by IRAK-dependent phosphorylation. As these experiments were all conducted by overexpression of IRAK1 or 2, it would significantly strengthen their conclusion if they carried out some knockdown experiments where they deplete endogenous IRAK1/2. Does this abolish the 14-3-3 interaction with Regnase1 in IL-1B treated cells?</p></disp-quote><p>We thank the reviewer for the suggestion. We have previously showed that double knockout of <italic>Irak1</italic> and <italic>Irak2</italic> abolished the LPS-induced phosphorylation of Regnase-1, resulting in the disappearance of slowly migrating Regnase-1 in immunoblot analysis (Iwasaki et al., 2011). To further investigate if IRAK1/2 are necessary for the association between Regnase-1 and 14-3-3 as well as the phosphorylation of Regnase-1, we utilized CRISPR-Cas9 system by introducing pX459 plasmids, which express Cas9 and gRNAs for <italic>IRAK1</italic> and <italic>IRAK2</italic> in HeLa cells, followed by the selection with puromycin. Then we transfected HA-14-3-3ε in the puromycin-resistant cells. We confirmed that the cells lack IRAK1 expression by immunoblot analysis, although antibodies detecting endogenous human IRAK2 were not available which precluded the evaluation of <italic>IRAK2</italic> knockout efficiency. It is known that IL-1β stimulation induces various post translational modification of IRAK1, rendering the detection of IRAK1 unable by immunoblot analysis (Vollmer et al., 2017; PMID: 28512203). Consistently, we also did not detect the clear band of IRAK1 in IL-1β-stimulated control sample. Consistent with our previous finding using MEFs (Iwasaki et al., 2011), phosphorylation of Regnase-1 is diminished in cells transfected with pX459 for <italic>IRAK1/2</italic> (Figure 2—figure supplement 3). Furthermore, immunoprecipitation with HA-14-3-3ε revealed that the association of Regnase-1 and 14-3-3 was also diminished by depletion of IRAK1/2 expression. These results indicate that IRAK1/2 (at least IRAK1 in HeLa cells) is necessary for Regnase-1-14-3-3 interaction.</p><disp-quote content-type="editor-comment"><p>4. While I agree with the authors that their data support different phosphorylated serine residues supporting interactions with either 14-3-3 or TRCP, I don't think that their data specifically support mutually exclusive interactions between the two. A convincing competition experiment to test this may be to express both 14-3-3 and TRCP at different levels along with Regnase1. This would allow them to immunopreciptate a tagged Regnase 1 and see if, for example, increasing TRCP expression increases its association with Regnase1, while decreasing the association of 14-3-3 with Regnase1.</p></disp-quote><p>We thank the reviewer for the suggestion. The other reviewers also pointed out the wording, &quot;mutually exclusive&quot;. As we described in our response to the Reviewer #2, we corrected the wording.</p><disp-quote content-type="editor-comment"><p>5. For Figure 5G, the authors should also test specific Serine-to-Alanine mutants to see if they impact RNA binding. This could be accomplished with a mutant that cannot bind TRCP (to keep it stable), and compare it to a mutant that cannot bind both TRCP and 14-3-3. This would allow the authors to make conclusions on a Regnase1 mutant that did not contain additional bacterial stretches to it, which could bind to proteins other than 14-3-3 that they don't know about.</p></disp-quote><p>We thank the reviewer for raising the concern. We agree that introduction of the ExoS sequence may cause effects on Regnase-1 other than binding with 14-3-3. The difficulty of using the S513A mutant to evaluate the functional effect of 14-3-3 on Regnase-1 is that not all the overexpressed Regnase-1 is phosphorylated by IL-1β stimulation. Particularly, IL-1β-induced phosphorylation rate of overexpressed Regnase-1 is not so high (e.g., Figure 2D, 3A, and 3B). Since RNA-immunoprecipitation requires large amount of Regnase-1 to evaluate its RNA-binding capacity, we feel it difficult to finely detect the changes in the binding of Regnase-1 WT and S513A to mRNA in response to IL-1β stimulation. Thus, utilizing an ExoS mutant and its control, an ExoSAAA mutant, was the most practical way to elucidate the mechanism how 14-3-3 affects the function of Regnase-1, although we agree that further studies are required to conclude that 14-3-3 inhibits Regnase-1-RNA binding in vivo. We discuss the requirement of future studies in the Discussion section.</p><disp-quote content-type="editor-comment"><p>6. Similarly, the final conclusion of the manuscript is that 14-3-3 binding to Regnase1 localizes to the nucleus. However, this is based on Regnase mutants that utilize bacterial stretches that bind 14-3-3 proteins (and potentially other proteins as well). To strengthen their data, the authors should utilize a Regnase mutant that cannot bind to TRCP and/or contains mutations of serine residues such that it cannot bind 14-3-3 proteins. These mutants could then be used to test if nuclear localization is impaired without adding additional bacterial protein stretches to it.</p></disp-quote><p>We thank the reviewer for the criticism. Similar to the aforementioned response to comment #5, the difficulty in the use of Regnase-1-overexpressing cells is that IL-1β-induced phosphorylation rate of overexpressed Regnase-1 is not so high (e.g., Figure 2D, 3A, and 3B), thus it is hard to assess the IL-1β-induced changes in intracellular dynamics of Regnase-1 by using overexpression system. Therefore, we believe that the use of the ExoS system is the most practical way to assess the role of Regnase-1-14-3-3 binding, although further studies are necessary to elucidate the function and detailed mechanism of nuclear and cytoplasmic shuttling of Regnase-1 in vivo. We discussed these issues in the Discussion section.</p></body></sub-article></article>